

**Thursday 28 February**

1145 - 1315

Hall A

***Scientific Meeting of the Glaucoma Section of the Hungarian Ophthalmological Society***

Chair Gabor Hollo

005/ OR2

Time	Title	Poster Board Number	Abstract Number	Reference I
1145	1 OPENING G.Hollo, Hungary (*)		653.00	10951
1155	2 OPTIC NERVE HEAD, RETINAL NETVE FIBER LAYER AND VISUAL FIELD TESTING IN THE DIAGNOSIS AND MANAGEMENT OF GLAUCOMA: NEW SOFTWARES, NEW VIEWPOINTS G.Hollo, Hungary (*)		543.00	10951
1215	3 SAFETY OF TOPICAL BETA-BLOCKERS IN THE TREATMENT OF GLAUCOMA P.Sziklai, Hungary (*)		542.00	11282
1235	4 THE PHYLOSOPHY OF GLAUCOMA TREATMENT		567.00	3139
1255	5 DISCUSSION		260.00	11248
1315	6 BREAK		102.00	11248

1400 - 1445

Hall A

***Discussion: Off Label Use - Inevitable, Essential or Dangerous***

Chair Roger Vogel

010/ OR3

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	1 SPEAKERS FOR OOF LABEL USE SESSION		105.00	11248

1445 - 1545

Hall A

***Discussion: New Drugs - Not Always As Useful As They Seem?***

Chair Roger Vogel

015/ OR5

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	1 SPEAKERS FOR USEFULNESS OF NEW DRUGS SESSION		546.00	11248
1545	4 COFFEE BREAK		103.00	11248

**Thursday 28 February**

1615 - 1745

Hall A

***Clinical Research Networks in Ophthalmology: A Step Forward in Drug Development***

Chair José Cunha-Vaz

020/ OR7

Time	Title	Poster Board Number	Abstract Number	Reference I
1615	1 DRCR.net (USA) B.Kuppermann, USA (*)		133.00	10935
1630	2 A EUROPEAN NETWORK OF CERTIFIED CLINICAL TRIALS CENTRES OF OPTHALMOLOGY - EVI.CT.SE J.Cunha-Vaz, Portugal (*)		1199.00	11144
1645	3 FDA PERSPECTIVE ON MEDICAL DEVICES M.Eydelman, USA (*)		135.00	11248
1700	4 FDA PERSPECTIVE ON DRUG DEVELOPMENT W.Chambers, USA (*)		138.00	11248
1715	5 EMEA PERSPECTIVE K.Wickstroem, Sweden (*)		136.00	22
1730	6 CRO PERSPECTIVE I.Schauwecker, Switzerland (*)		137.00	11272

1400 - 1445

Hall B

***Retinal Light Damage***Chair Akihiro Ohira  
Robert Eugene Anderson

025/ OR4

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	1 INHIBITORY EFFECT OF TEA CATECHINS ON LIPID PEROXIDATION INDUCED BY ROSE BENGAL AND BLUE LIGHT EXPOSURE IN PORCINE RETINAL HOMOGENATE T.Nakanishi-Ueda, Japan (*) ; T.Ueda, Japan ; M.Aburada, Japan ; T.Shimada, Japan ; R.Koide, Japan ; H.Yasuhara, Japan		1033.00	7929
1415	2 INTENSIFICATION OF ENDOGENOUS NEUROPROTECTIVE SIGNALS AGAINST RETINAL LIGHT DAMAGE. ITS POSSIBLE THERAPEUTIC APPLICATION FOR RETINAL DEGENERATIVE DISEASES M.Tanito, Japan (*)		1096.00	9036
1430	3 STRATEGIES FOR USING ANTIOXIDANTS IN THE TREATMENT OF INHERITED AND ENVIRONMENTALLY-INDUCED RETINA R.Anderson, USA (*) ; C.Rao, USA ; M.Mandal, USA ; M.Tanito, Japan		1243.00	10943

**Thursday 28 February**

1445 - 1545

Hall B

***Vitreolytics - PVR - Retinal Neovascularisation***Chair Baruch D. Kuppermann  
José Cunha-Vaz

030/ OR8

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	1 MICROPLASMIN M.De Smet, The Netherlands (*)		280.00	4349
1500	2 VITRESOLVE AS A SURGICAL ADJUVANT FOR VITRECTOMY B.Kupermann, USA (*)		281.00	10935
1515	3 CHRONIC BRVO IN PRIMATES: A FUNCTIONAL AND ANATOMICAL EVALUATION J.Burke, USA (*) ; K.Zhang, USA ; A.Vilupuru, USA ; T.Lin, USA ; Y.Li, USA ; M.Escobar, USA ; W.Orilla, USA ; C.Ghosn, USA ; L.Wheeler, USA		1344.00	1721
1530	4 ANTI-ANGIOGENIC THERAPY IN RETINOPATHY OF PREMATURITY K.Drenser, USA (*) ; M.Trese, USA ; A.Capone Jr., USA ; N.Sund, USA ; W.Dailey, USA ; K.Sonmez, USA		1127.00	10672

1615 - 1745

Hall B

***Systematic Anti-Metabolites***

Chair Susan Lightman

035/ OR12

Time	Title	Poster Board Number	Abstract Number	Reference I
1615	1 BIOLOGIC THERAPY FOR UVEITIS J.Rosenbaum, USA (*)		1166.00	11132
1625	2 MYCOPHENOLATE MOFEIL IN UVEITIS S.Lightman, UK (*)		155.00	7204
1635	3 INTRAOCULAR METHOTREXATE IN UVEITIS S.Taylor, UK (*)		1316.00	10716
1645	4 TOPICAL ANTI-METABOLITES - , 5FU AND MMC IN THE MANAGEMENT OF UVEITIC GLAUCOMA P.McCluskey, UK (*)		1309.00	11017
1655	5 PHASE 2/3 CLINICAL TRIALS OF A NOVEL CALCINEURIN INHIBITOR - LX 211 - FOR THE TREATMENT OF NON-INFECTIOUS UVEITIS Q.Nguyen, USA (*)		1212.00	10140
1705	6 COMBINED THERAPY FOR CHOROIDAL NEOVASCULARIZATION UVEITIS ASSOCIATED F.Mandelblum, Venezuela (*) ; J.Mandelblum, Venezuela ; J.Murcia, Venezuela ; N.Ramirez, Venezuela		1118.00	7380
1715	7 THE ANTI-INFLAMMATORY EFFECTS OF CURCUMA LONGA AND BERBERIS ARISTATA IN ENDOTOXIN-INDUCED UVEITIS IN RABBITS S.Gupta, India (*) ; R.Agarwal, India ; N.Galpalli, India ; V.Kalai Selvan, India ; P.Agarwal, India ; S.Srivastava, India ; S.Agrawal, India ; R.Saxena, India		1192.00	11175
1725	8 ORAL TALK FOR SYSTEMIC ANTI-METABOLITES		160.00	11248
1735	9 DISCUSSION		167.00	11248

**Friday 29 February****0730 - 0900****Hall B*****Clinical Courses: Challenging Cases In Corneal Diseases****Chair* Manfred Zierhut

040/ C2

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference</b>
1	CHALLENGING CASES IN CORNEAL DISORDERS M.Zierhut, Germany (*)		1162.00	9489
0730	PANEL: R. DENA, USA, R. NEUMANN, ISRAEL, M. ZIERHUT, GERMANY		140.00	11248

**0900 - 0945****Hall A*****Combination Drug-Laser-Surgical Approaches****Chair* Baruch D. Kuppermann  
José Cunha-Vaz

045/ OR10

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference</b>
0900	1 COMBINATION PDT FOR CNV IN AMD - VERITAS TRIAL P.Kaiser, USA (*) ; T.VERITAS Study Group		1300.00	6875
0910	2 TRIPLE COMBINATION THERAPY FOR CNV IN AMD A.Augustin, Germany (*)		287.00	11047
0920	3 A STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF RADIOTHERAPY AND BEVACIZUMAB (AVASTIN®) FOR THE TREATMENT OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION (CNV) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD) J.Heier, USA (*) ; M.Farah, Brazil ; J.Duprat, Brazil ; M.Avila, Brazil ; G.Fujii, Brazil ; J.Rossi, Brazil ; A.Santos, Mexico ; B.Woodward, USA ; M.Yaqub, USA ; J.Nau, USA		1330.00	10249
0930	3 COMBINATION THERAPY FOR DIABETIC MACULA EDEMA A.Augustin, Germany (*)		290.00	11047
0940	5 DISCUSSION		291.00	11248

**0945 - 1030****Hall A*****Neuroprotection In Neuroretinal Disease****Chair* Leonard A. Levin

050/ OR13

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference</b>
0945	1 AXOPROTECTION IN OPTIC NEUROPATHIES K.Martin (*)		1157.00	9741
1000	2 NEUROPROTECTION OF CONE PHOTORECEPTOR CELLS : FROM CELL THERAPY TO PROTEIN THERAPY J.Sahel, France (*) ; Y.Yang, France ; A.Danan, France ; E.Clerin, France ; J.Bennet, USA ; S.Mohand-Said, France ; T.Leveillard, France		1083.00	11075
1015	3 TRANSCRIPTION FACTORS AND THE SURVIVAL OF SENSORY NEURONS M.Kanje, Sweden (*)		154.00	10628
1030	7 COFFEE BREAK		152.00	11248

**Friday 29 February**

1100 - 1230

Hall A

**Research And Development for CNV in AMD - Part 1**Chair Baruch D. Kuppermann  
José Cunha-Vaz

055/ OR14

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	1 SMALL MOLECULE INTEGRIN INHIBITOR J.Heier, USA (*)		1067.00	10249
1115	2 RTP801I: A NOVEL ANTI-ANGIOGENIC STRATEGY SUPERIOR TO AND COOPERATIVE WITH VEGF-A BLOCKADE IN SUPPRESSING CNV J.Ambati, USA (*) ; M.Nozaki, USA ; B.Raisler, USA ; I.Mett, USA ; N.Notkin, USA ; I.Papismadov, USA ; L.Shalom, USA ; A.Takeda, USA ; J.Baffi, USA ; E.Feinstein, USA		1323.00	2335
1130	3 VEGF TRAP FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Q.Nguyen, USA (*) ; T.CLEAR-IT Investigators		1338.00	10140
1145	4 SIRNA-027 (AGN 211745) FOR AMD P.Kaiser, USA (*) ; E.Quinlan, USA		1301.00	6875
1200	6 APPROACHES TO MANAGING CHOROIDAL NEOVASCULARIZATION: LOOKING BEYOND VEGF PATHWAY Q.Nguyen, USA (*)		1339.00	10140
1215	6 ACTIVATED COMPLEMENT COMPONENTS OF DRUSEN PROMOTE CHOROIDAL NEOVASCULARIZATION J.Ambati, USA (*) ; J.Baffi, USA ; M.Nozaki, USA ; B.Raisler, USA ; E.Sakurai, USA ; K.Zhang, USA ; J.Lambris, USA ; J.Sarma, USA ; A.Humbles, USA ; B.Ambati, USA		1325.00	2335
1230	7 LUNCH BREAK		108.00	11248

0730 - 0900

Hall A

**Clinical Course: Challenging Cases In Retinal Disorder**

Chair Antonia Jousen

060/ C1

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	1 PANEL: Q.D. NGUYEN, USA, A. JOUSSEN, GERMANY, H. HEIMANN, UK		139.00	11248

0900 - 1030

Hall B

**New Treatments For Dry Eyes**Chair Penny A. Asbell  
Shabtai Dickstein

065/ OR11

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	1 NEW TREATMENT FOR NEUROTROPHIC KERATITIS - CLINICAL TRIAL RESULTS T.Nishida, Japan (*)		141.00	10307
0910	2 ANTI-INFLAMMATORY STRATEGIES IN DRY EYE C.Baudouin, France (*)		1320.00	10963
0920	3 EVOLVING TRENDS IN OUR UNDERSTANDING OF INFLAMMATION AND IMMUNITY IN DRY EYE PATHOGENESIS R.Dana, USA (*)		1311.00	10966

**Friday 29 February**

0900 - 1030

Hall B

*New Treatments For Dry Eyes*Chair Penny A. Asbell  
Shabtai Dickstein

065/ OR11

Time	Title	Poster Board Number	Abstract Number	Reference I
0930	4 AN INTEGRATED APPROACH TO THE TREATMENT OF CHRONIC BLEPHARITIS M.Rolando, Italy (*)		143.00	9787
0940	5 ANTI-MICROBIAL PEPTIDES BIOENGINEERED FOR EPITHELIAL CELL SAFETY AND PATHOGEN KILLING R.Beuerman, Singapore (*) ; Z.Lei, Singapore ; J.Li, Singapore ; C.Verma, Singapore		1211.00	10956
0950	6 IS THERE A ROLE FOR NEUROGENIC INFLAMMATION IN DRY EYE? S.Bonini, Italy (*)		1345.00	2914
1000	7 REPOSITIONING MEDICATIONS AND IDEAS FOR DRY EYE AND OCULAR SURFACE E.Rocha, Brazil (*)		1280.00	9971
1010	8 INFLUENCE OF ASPIRIN TREATMENT ON LACRIMAL GLAND AND OCULAR SURFACE OF DIABETIC RATS E.Rocha, Brazil (*) ; C.Modulo, Brazil ; A.Jorge, Brazil ; A.Dias, Brazil ; A.Braz, Brazil ; R.Bertazolli Filho, Brazil		1169.00	9971
1016	9 BOTULINUM-A TOXIN (BAT) INJECTIONS DID NOT CAUSE WORSENING OF DRY EYE SYMPTOMS IN PATIENTS SUFFERING FROM BLEPHAROSPASM AND KERATOCONJUNCTIVITIS SICCA A.BERTA, Hungary (*) ; A.NAGY, Hungary ; A.FACSKO, Hungary ; M.ZAJACZ, Hungary		1034.00	2659
1022	10 LYOPHILIZED AMNION EXTRACT (AMX) E.Ghinelli, Italy (*) ; A.Gallazzi, Italy ; L.Vedovelli, Italy ; K.Kenyon, USA		1235.00	11196
1028	11 DISCUSSION		150.00	11248
1030	11 COFFEE BREAK		151.00	11248

1100 - 1230

Hall B

*Protecting The Retinal Ganglion Cells - Dreams And Reality*

Chair Hana Levkovitch-Verbin

070/ OR15

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	1 INCREASING OUTFLOW FACILITY TODAY AND TOMORROW P.Kaufman, USA (*)		1071.00	11071
1112	2 AXONAL SUSCEPTIBILITY IN GLAUCOMA - A NEW TARGET FOR NEUROPROTECTION H.Levkovitch-Verbin, Israel (*)		169.00	10289
1124	3 SIMILARITIES BETWEEN ALZHEIMER DISEASE AND GLAUCOMA - IMPLICATION FOR NOVEL TREATMENTS S.McKinnon, USA (*)		1154.00	7740
1136	4 GLAUCOMA AND THE BRAIN - IMPLICATIONS FOR NEUROPROTECTION N.Gupta, Canada (*)		1308.00	5477

**Friday 29 February**

1100 - 1230

Hall B

***Protecting The Retinal Ganglion Cells - Dreams And Reality***

Chair Hana Levkovitch-Verbin

070/ OR15

Time	Title	Poster Board Number	Abstract Number	Reference I
	N.Gupta, Canada (*)			
1148	5 LONG-TERM RESULTS OF BEVACIZUMAB FOR NEOVASCULAR GLAUCOMA J.Beutel, Germany (*) ; S.Peters, Germany ; M.Luke, Germany ; K.Bartz-Schmidt, Germany ; S.Grisanti, Germany		1027.00	11029
1156	6 SUPPORT FOR LIGHT BEING A RISK FACTOR IN OPTIC NEUROPATHIES LIKE GLAUCOMA N.Osborne, UK (*)		1050.00	8064
1204	7 THE ACTUAL EFFECT OF IOP ON THE NERVE FIBER LAYER LOSS IN PRIMARY OPEN-ANGLE GLAUCOM C.Ajtony, Hungary (*) ; Z.Balla, Hungary ; R.Fustos, Hungary ; B.Kovacs, Hungary		1148.00	10667
1212	8 INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF IRIS NEOVASCULARISATION FOLLOWING PROTON BEAM IRRADIATION OF UVEAL MELANOMAS L.Zografos, Switzerland (*) ; L.Chamot, Switzerland ; A.Schalenbourg, Switzerland		1156.00	9498
1220	9 PRIMARY TREATMENT OF GLAUCOMA: IS DRUG THERAPY ETHICAL? M.Belkin, Israel (*)		1175.00	34
1228	10 DISCUSSION		178.00	11248
1230	11 LUNCH BREAK		109.00	11248

1230 - 1330

Hall B

***Macular Edema In 2008 Sponsored By Allergan***Chair José-Alain Sahel  
Baruch D. Kuppermann

075/ SP7

Time	Title	Poster Board Number	Abstract Number	Reference I
1230	1 INTRODUCTION AND WELCOME J.Sahel, France (*) ; B.Kuppermann, USA		534.00	11075
1235	2 ADAPTIVE OPTICS FOR IMAGING OF RETINAL DISEASES J.Sahel, France (*)		458.00	11075
1245	3 THE MOLECULAR BASIS FOR AN ANTI-INFLAMMATORY APPROACH IN ME J.Burke, USA (*)		678.00	1721
1255	4 PHARMACOTHERAPY IN ME F.Bandello, Italy (*)		453.00	3009
1305	5 COMBINATION OR TRIPLE THERAPY IN ME A.Augustin, Germany (*)		566.00	11047

**Friday 29 February**

1230 - 1330

Hall B

***Macular Edema In 2008 Sponsored By Allergan***Chair José-Alain Sahel  
Baruch D. Kuppermann

075/ SP7

Time		Title	Poster Board Number	Abstract Number	Reference I
1315	6	DRUG DELIVERY AND STEROID FORMULATIONS FOR ME B.Kuppermann, USA (*)		700.00	10935
1325	7	DISCUSSION AND CLOSE J.Sahel, France (*) ; B.Kuppermann, USA		689.00	11075
1330	8	POSTER REVIEWING		153.00	11248

0900 - 1030

Hall C

***Systematic Drugs***Chair Stephen C. Foster  
Ron Neumann

080/ OR34

Time		Title	Poster Board Number	Abstract Number	Reference I
	1	PANEL: S.C. FOSTER, USA, S. LIGHTMAN, UK, R. NEUMANN, ISRAEL		366.00	11248
0900	2	USE OF SYSTEMIC STEROIDS IN OCULAR INFLAMMATORY DISEASE W.Ayliffe, UK (*)		1346.00	2366
0915	3	CYCLOSPORIN A AND TACROLIMUS A.Okada, Japan (*)		1032.00	8037
0930	4	ALKYLATING AGENTS IN OCULAR INFLAMMATORY DISEASES M.Sainz de la Maza, Spain (*)		1227.00	11193
0945	5	THE USE OF METHOTREXATE FOR OCULAR INFLAMMATORY DISEASES J.Rosenbaum, USA (*)		1167.00	11132
1000	6	WHAT ARE COMING TO THE CLINICS FOR OCULAR INFLAMMATORY DISEASES? Q.Nguyen, USA (*)		1340.00	10140
1015	7	GAP ANALYSIS: THE UNMET MEDICAL NEED (A CALL FOR COMPANIES) S.Foster, USA (*)		324.00	5044
1030	8	COFFEE BREAK		545.00	11248



**Friday 29 February****1100 - 1230****Hall C*****Ocular Imaging: The Next Generation****Chair* Sara Krupsky

085/ OR16

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference I</b>
1100	1 LOCATION VERSUS FOVEA MAPPING IMPROVEMENTS J.Cunha-Vaz, Portugal (*)		180.00	11144
1115	2 NEXT GENERATION IMAGING TOOLS S.Krupsky, Israel (*)		181.00	7032
1130	3 CRITICAL STEPS IN DEVELOPING NEW OCULAR IMAGING MODALITIES W.Chambers, USA (*)		183.00	3927
1145	4 MULTIMODAL IMAGING - THE BENEFITS AND PROMISES OF INTEGRATION M.De Smet, The Netherlands (*)		185.00	4349
1200	5 PRECISION AND REPRODUCIBILITY WITH SPECTRAL-DOMAIN OCT J.Heier, USA (*)		1069.00	10249
1215	6 DISCUSSION		184.00	11248
1230	7 LUNCH BREAK		110.00	11248

**1400 - 1545****Hall A*****Diabetic Macular Edema****Chair* Baruch D. Kuppermann  
José Cunha-Vaz

090/ OR17

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference I</b>
1400	1 MANAGEMENT OF DIABETIC MACULAR EDEMA J.Cunha-Vaz, Portugal (*)		1202.00	11144
1412	2 RANIBIZUMAB FOR DIABETIC MACULAR EDEMA D.Do, USA (*)		1341.00	10671
1424	3 BEVACIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA A.Loewenstein, Israel (*) ; S.Soudri, Israel		1282.00	7236
1436	4 TREATMENT OF DIABETIC MACULAR EDEMA (DME) WITH PEGAPTANIB (MACUGENÂ®) - TWO-YEAR FOLLOW-UP E.Ergun, Austria (*)		1219.00	10972
1448	5 INTRAVITREAL TRIAMCINOLONE J.Jonas, Germany (*)		1001.00	6697
1500	6 THE HELICAL COIL DRUG TECHNOLOGY FOR DME E.DeJuan, USA (*)		302.00	10282

**Friday 29 February**

1400 - 1545

Hall A

***Diabetic Macular Edema***Chair Baruch D. Kuppermann  
José Cunha-Vaz

090/ OR17

Time	Title	Poster Board Number	Abstract Number	Reference I
1512	7 INTRAVITREAL SUSTAINED-RELEASE TRIAMCINOLONE MICROSPHERES SYSTEM: SAFETY AND A PRELIMINARY REPORT OF ITS POTENTIAL USEFULNESS FOR THE TREATMENT DIABETIC MACULAR EDEMA J.Cardillo, Brazil (*)		1289.00	9940
1524	8 MEDIDURÁ,ç/FLUOCINOLONE ACETONIDE IMPLANT FOR DME J.Figueira, Portugal (*)		1348.00	10633
1536	9 DISCUSSION		306.00	11248
1545	10 COFFEE BREAK		111.00	11248

1615 - 1745

Hall A

***Diabetic Macular Edema and Pharmacologic Inhibition of Diabetic Retinopathy***

Chair Arup Das

095/ OR20

Time	Title	Poster Board Number	Abstract Number	Reference I
1615	1 FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT (RETISERT) FOR DIABETIC MACULAR EDEMA: 4-YEAR RESULTS OF A MULTICENTER CLINICAL TRIAL D.Elliott, USA (*) ; T.Comstock, USA		1226.00	10636
1625	2 DEXAMETHASONE LIPID EMULSION FOR DME G.Lambert, France (*)		305.00	10155
1635	3 MICROPULSE LASER TREATMENT IN DIABETIC MACULAR EDEMA V.Chong, UK (*) ; J.Figueira, Portugal ; J.Khan, UK ; S.Nunes, Portugal ; A.Rosa, Portugal ; J.Faria de Abreu, Portugal ; J.Cunha-Vaz, Portugal		1312.00	3970
1645	4 UROKINASE SYSTEM: A POTENTIAL TARGET FOR EARLY DIABETIC RETINOPATHY A.Das, USA (*)		1189.00	4339
1700	5 INHIBITION OF EARLY DIABETIC RETINOPATHY USING ANTI-INFLAMMATORY DRUGS T.Kern (*)		467.00	10718
1715	6 ANTI-OXIDANTS AND DIABETIC RETINOPATHY R.Kowluru, USA (*) ; M.Kanwar, USA		1142.00	11
1730	7 NEUROTROPHIN APPROACHES FOR DIABETIC RETINOPATHY T.Gardner, USA (*) ; M.Losiewicz, USA ; P.Fort, USA ; T.Lowe, USA ; G.Misra, USA ; R.Singh, USA		1095.00	11082

**Friday 29 February**

1400 - 1445

Hall B

***Ocular Inflammation Lutein and Zeaxanthin: Role in ARMD******Sponsored by Bausch & Lomb****Chair* Maurizio Rolando

100/ SP2

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	1 UPDATE ON NON STERODIAL ANTI-INFLAMMATORY DRUGS B.Bodaghi, France (*)		189.00	10380
1410	2 MANAGEMENT OF INFLAMMATION IN CATARACT SURGERY WITH A NEW STEROID: LOTEPIREDNOL ETABONATE C.Slonim, USA (*)		186.00	11259
1420	3 LOTEPIREDNOL ETABONATE AND OCULAR SURFACE INFLAMMATION M.Rolando, Italy (*)		190.00	9787
1430	4 LUTEIN AND ZEAXANTHIN: ROLE IN ARMD S.Beatty, Ireland (*)		191.00	11260
1445	5 CONCLUSION M.Rolando, Italy (*)		343.00	9787

1445 - 1545

Hall B

***The Serra Metzner Blood Flow Symposium****Chair* Alon Harris

105/ OR19

Time	Title	Poster Board Number	Abstract Number	Reference I
	1 IT IS OUR HONOR TO COMMEMORATE DR. SERRA METZNER, A FRIEND, ISOPT BOARD MEMBER AND A SPECIAL CONTRIBUTOR TO THE 2000 ISOPT MEETING IN A SPECIAL SESSION DEDICATED TO HIS MEMORY		205.00	11248
1445	2 AUTONOMIC VARIABILITY ON IOP - BASIC CONCEPTS C.Marques-Neves, Portugal (*) ; C.Gonçalves, Portugal ; A.Figueiredo, Portugal ; M.Monteiro-Grillo, Portugal ; L.Silva-Carvalho, Portugal ; I.Rocha, Portugal		1331.00	10686
1455	3 AUTONOMIC VARIABILITY ON IOP - CLINICAL CONCEPTS C.Goncalves, Portugal (*) ; C.Neves, Portugal ; A.Figueiredo, Portugal ; J.Couceiro, Portugal ; T.Gomes, Portugal ; M.Monteiro-Grillo, Portugal ; M.Bento, Portugal ; L.Silva-Carvalho, Portugal ; A.Castanheira-Dinis, Portugal ; M.Rocha, Portugal		1144.00	11104
1505	4 ARE THERE ANY NON-HYPOTENSIVE EFFECTS OF ANTIGLAUCOMA DRUGS? A.Figueiredo, Portugal (*) ; C.Goncalves, Portugal ; J.Couceiro, Portugal ; C.Neves, Portugal ; L.Silva-Carvalho, Portugal ; M.Grillo, Portugal		1271.00	11215
1515	5 NON-PRESSURE DEPENDENT GLAUCOMA: A CLINICAL APPROACH T.Gomes, Portugal (*) ; E.Guerra, Portugal ; C.Goncalves, Portugal ; A.Figueiredo, Portugal ; C.Neves, Portugal ; A.Aguilar, Portugal		1151.00	10685
1525	6 THE EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN®) ON OCULAR PULSE AMPLITUDE IN NEOVASCULAR AGE RELATED MACULAR DEGENERATION E.Rechtman, Israel (*) ; A.Harris, USA ; I.Stalmans, Belgium ; A.Leys, Belgium ; J.Van Calster, Belgium ; J.Glovinsky, Israel ; J.Moisseev, Israel		1044.00	10651
1535	7 FUNCTIONAL IMAGING OF THE EYE L.Kagemann, USA (*) ; A.Harris, USA		1307.00	6873

**Friday 29 February****1445 - 1545****Hall B*****The Serra Metzner Blood Flow Symposium****Chair* Alon Harris

105/ OR19

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference I</b>
1545	8 COFFEE BREAK		112.00	11248

**1615 - 1700****Hall B*****New Pathophysiological And Therapeutic Approaches In Dry Eye******Sponsored By Novagali****Chair* Christophe Baudouin

110/ SP3

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference I</b>
1615	1 THE VICIOUS CIRCLES IN DRY EYE SYNDROME: A NEW MECHANISTIC APPROACH C.Baudouin, France (*)		1318.00	10963
1625	2 THE TOLE OF TEAR OSMOLARITY IN THE PATHOGENESIS AND DIAGNOSIS OF DRY EYE DISEASE M.Lemp, USA (*)		210.00	7073
1635	3 LIPID-RELATED DRY EYES: CLINICAL ASSESSMENT AND DIAGNOSIS M.Guillon, UK (*)		211.00	5466
1645	4 CATIONORM - A CATIONIC EMULSION TO TREAT DRY EYE M.Amrane, France (*)		212.00	11159
1655	5 DISCUSSION		214.00	11248

**1700 - 1745****Hall B*****Anterior Segment****Chair* Penny A. Asbell

115/ OR23

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference I</b>
1700	1 CONFOCAL IMAGE ANALYSIS OF CORNEAL FUNGAL INFECTIONS R.Beurman, Singapore (*) ; S.Dua, USA		1223.00	10956
1710	2 UTILITY OF ANTERIOR SEGMENT OCT IN ASSESSMENT OF THE CORNEA AND ANTERIOR SEGMENT J.Mehta, Singapore (*) ; D.Tan, Singapore		1171.00	11014
1720	3 ORA, CORNEAL HYSTERESIS MEASUREMENT P.Asbell, USA (*)		215.00	2035
1730	4 NEW GENERATION CORNEAL TOPOGRAPHY: ADVANTAGES AND CLINICAL IMPLICATIONS Ö.Uçakhan-Gündüz, Turkey (*)		1329.00	11261
1740	5 DISCUSSION		221.00	11248

**Friday 29 February****1400 - 1545****Hall C*****Latest Advances In Ocular Drug Discovery***Chair Thomas Yorio  
Ganesh Prasanna

120/ OR18

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	1 OPIOID AGONISTS: POTENTIAL THERAPY FOR ISCHEMIC RETINAL DISORDERS C.Crosson, USA (*) ; S.Husain, USA		1286.00	1727
1415	2 SIGMA RECEPTORS AND NEUROPROTECTION K.Tchedre, USA ; T.Yorio, USA (*)		1132.00	1764
1430	3 RNA INTERFERENCE: PROMISING NEW THERAPY FOR OCULAR DISORDERS R.Patil, USA (*)		1224.00	10139
1445	4 BIOMARKERS IN OCULAR DRUG DISCOVERY G.Prasanna, USA (*)		1322.00	1749
1500	5 CHARGED NANOPARTICLES DELIVERY TO THE EYE USING HYDROGEL IONTOPHORESIS J.Frucht-Pery, Israel (*) ; E.Eljarrat-Binstock, Israel ; A.Domb, Israel		1328.00	5074
1510	6 THE DEVELOPMENT AND APPLICATION OF A COMPUTATIONAL MODEL OF OCULAR PIGMENT BINDING (OPB) IN DRUG DISCOVERY C.Stoner, USA (*) ; A.Clouser-Roche, USA ; L.Goulet, USA ; M.Batugo, USA ; M.Zientek, USA		1066.00	11069
1520	7 ORALLY ACTIVE MULTIFUNCTIONAL ANTIOXIDANTS FOR THE TREATMENT OF OCULAR DISEASES P.Kador, USA (*) ; J.Randazzo, USA ; H.Jin, USA ; K.Blessing, USA		1042.00	11007
1530	8 THE DEVELOPMENT OF EXTENDED PROTOCOLLS FOR FUNCTION TESTING IN TOXIC NEUROOPHTHALMOLOGIC DISORDERS E.Zrenner, Germany (*)		1116.00	9791
1540	9 DISCUSSION		200.00	11248
1545	10 COFFEE BREAK		113.00	11248

**1615 - 1745****Hall C*****Drug Delivery***Chair Robert Gurny  
Diane Tang-Liu

125/ OR21

Time	Title	Poster Board Number	Abstract Number	Reference I
1615	1 NANOPARTICLES FOR GENE DELIVERY TO THE EYE U.Kompella (*)		1292.00	10719
1625	2 MODELING CONSIDERATIONS OF OCULAR DRUG DELIVERY TO THE BACK OF THE EYE S.Lee, USA (*) ; D.D'Argenio, USA ; R.Moats, USA ; P.Hughes, USA ; W.Blanda, USA ; S.Whitcup, USA ; M.Robinson, USA		1022.00	10720
1635	3 INTRAOCULAR DELIVERY OF NUCLEIC ACIDS USING TROJAN DELIVERY SYSTEMS E.Fattal, France (*) ; A.Gomes Dos Santos, France ; F.Behar-Cohen, France ; A.Bochot, France		1293.00	10740

**Friday 29 February**

1615 - 1745

Hall C

**Drug Delivery**Chair Robert Gurny  
Diane Tang-Liu

125/ OR21

Time	Title	Poster Board Number	Abstract Number	Reference I
1645	4 DELIVERY OF TOPICALLY APPLIED ANTIBODY FRAGMENTS TO THE BACK OF THE EYE D.Urech, Switzerland (*)		223.00	11147
1655	5 BIODEGRADABLE BIOPOLYMER DRUG DELIVERY SYSTEM ASSOCIATED WITH INTRAOCULAR LENS IN RABBITS Y.Guex-Crosier, Switzerland (*) ; S.Eperon, Switzerland ; L.Bossy-Nobs, Switzerland ; R.Gurny, Switzerland		1279.00	11074
1705	6 CATIONIC EMULSIONS: POTENTIAL INTRAOCULAR NANOCARRIERS FOR ANTISENSE OLIGONUCLEOTIDES T.Hagigit, Israel ; M.Abdulrazik, Israel ; F.Behar-Cohen, France ; G.Lambert, France ; S.Benita, Israel (*)		1186.00	3087
1715	7 WATER-SOLUBLE CYCLOSPORINE A PRODRUG FOR THE DELIVERY TO THE EYE L.Bossy, Switzerland (*) ; F.Lallemand, Switzerland ; E.Varesio, Switzerland ; G.Hopfgartner, Switzerland ; F.Behar-Cohen, France ; M.Berdugo-Polak, France ; R.Gurny, Switzerland		1231.00	9731
1725	8 OCULAR ELECTROTRANSFER: A NEW METHOD FOR THE SUSTAINED INTRAOCULAR PRODUCTION OF THERAPEUTIC PROTEINS F.Behar-Cohen, France (*) ; E.Touchard, France ; L.Kowalczyk, France ; P.Bigey, France ; J.Jeanny, France ; D.Scherman, France ; D.BenEzra, Israel		1152.00	11052
1735	9 THE IMPACT OF MELANIN ON OCULAR KINETICS C.Wilson, UK (*)		1305.00	11154

**Saturday 1 March**

0730 - 0900

Hall B

***Clinical Courses: Challenging Cases In Uveal Inflammation***

Chair Manfred Zierhut

130/ C4

Time	Title	Poster Board Number	Abstract Number	Reference I
	1 CHALLENGING CASES IN UVEAL INFLAMMATION M.Zierhut, Germany (*)		1161.00	9489
0730	1 PANEL: C. DE SMET, THE NETHERLANDS, M. ZIERHUT, GERMANY, C. PAVESIO, UK		231.00	11248

0900 - 1030

Hall A

***Dry AMD***Chair Baruch D. Kuppermann  
José Cunha-Vaz

135/ OR24

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	1 GENISTEIN FOR AMD E.De Juan, USA (*)		370.00	10282
0912	2 OT-551 TOPICAL ANTIOXIDANT THERAPY OF GEOGRAPHIC ATROPHY D.Boyer, USA (*)		1193.00	2558
0924	3 NOVEL CONCEPTS IN AMD THERAPY: COMPLEMENT INHIBITION C.Francois, USA (*)		1170.00	10994
0936	4 RETINOIDS FOR AMD E.De Juan, USA (*)		360.00	10282
0948	5 NUTRITIONAL MODIFICATION OF MACULAR DEGENERATION M.Cooney, USA (*)		1159.00	11115
1000	6 PHASE II/III STUDIES OF ENCAPSULATED CNTF SECRETING CELL IMPLANT (NT-501) IN PATIENTS WITH DRY AMD OR RETINITIS PIGMENTOSA W.Tao, USA (*)		1179.00	11018
1012	7 DEVELOPMENT OF TOPICALLY APPLIED MODULATORS OF OCULAR OXIDATIVE STRESS Y.Han, USA ; S.Reid, USA ; K.Phan, USA ; N.Tsivkovskaia, USA ; T.Bui, USA ; N.Mata, USA (*)		1281.00	10723
1024	8 DISCUSSION		350.00	11248
1030	9 COFFEE BREAK		114.00	11248

**Saturday 1 March**

1145 - 1230

Hall A

**Macular Edema**Chair Baruch D. Kuppermann  
José Cunha-Vaz

140/ OR27

Time	Title	Poster Board Number	Abstract Number	Reference I
1145	1 RANIBIZUMAB FOR MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSIONS; IMPLICATION OF VEGF AS A CRITICAL STIMULATOR P.Campochiaro, USA (*); G.Hafiz, USA; S.Shah, USA; Q.Nguyen, USA; H.Ying, USA; D.Do, USA; E.Quinlan, USA; I.Zimmer-Galler, USA; J.Haller, USA; S.Solomon, USA; J.Sung, USA; Y.Hadi, USA; K.Janjua, USA; N.Jawed, USA; D.Choy, USA; J.Arron, USA		1178.00	3876
1152	2 BEVACIZUMAB FOR MACULAR EDEMA DUE TO VEIN OCCLUSION D.Do, USA (*)		1342.00	10671
1159	3 1-YEAR STUDY OF PEGAPTANIB (MACUGENÂ®) FOR TREATMENT OF MACULAR EDEMA FOLLOWING CENTRAL RETINAL VEIN OCCLUSION (CRVO) A.Loewenstein, Israel (*)		1252.00	7236
1206	4 TRIAMCINOLONE FOR VEIN OCCLUSION J.Jonas, Germany (*)		349.00	6697
1213	5 EVALUATION OF AN INTRAVITREAL FLUOCINOLONE ACETONIDE (FA) IMPLANT VS STANDARD SYSTEMIC THERAPY IN NON INFECTIOUS POSTERIOR UVEITIS C.Pavesio, UK (*)		1214.00	11184
1220	6 PHARMACOKINETICS OF A DEXAMETHASONE POSTERIOR SEGMENT DRUG DELIVERY SYSTEM IN VITRECTOMIZED AND NON-VITRECTOMIZED EYES B.Kuppermann, USA (*); D.Welty, USA; J.Lin, USA; W.Orilla, USA; M.Robinson, USA; S.Whitcup, USA		1324.00	10935
1227	7 DISCUSSION		368.00	11248
1230	8 LUNCH BREAK		117.00	11248
1230	9 POSTER REVIEWING		265.00	11248

0730 - 0900

Hall A

**Clinical Courses: Challenging Cases In External Eye Diseases**

Chair Christoph Deuter

145/ C3

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	1 PANEL: C. DEUTER, GERMANY, A. LEONARDI, ITALY, C. BAUDOUIN, FRANCE		230.00	11248

0900 - 0945

Hall B

**New Approaches To Treatment Of Ocular Diseases****Sponsored By Senju**Chair Hidetoshi Yamashita  
Hideyuki Sakaki

150/ SP4

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	1 REGULATION OF EOSINOPHILIC CONJUNCTIVAL INFLAMMATION AT LATE-PHASE REACTION BY PROSTAGLANDIN E RECEPTOR SUBTYPE EP3 EXPRESSED IN OCULAR SURFACE EPITHELIUM S.Kinoshita, Japan (*); M.Ueta, Japan; T.Matsuoka, Japan; S.Narumiya, Japan		1295.00	10981
0915	2 THE VARIOUS TREATMENT MODALITIES FOR MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION		1297.00	10983



**Saturday 1 March**

0900 - 0945

Hall B

*New Approaches To Treatment Of Ocular Diseases**Sponsored By Senju*Chair Hidetoshi Yamashita  
Hideyuki Sakaki

150/ SP4

Reference I

Time	Title	Poster Board Number	Abstract Number	Reference I
	T.Yamamoto, Japan (*)			
0930	3 CALPAIN INHIBITOR, SNJ-1945, FOR TREATMENT OF RETINAL DISEASES H.Sakaki, Japan (*) ; J.Inoue, Japan ; T.Oka, Japan ; E.Nakajima, USA ; A.Ohtori, Japan ; M.Azuma, USA		1180.00	10984

0945 - 1030

Hall B

*Dry Eye Trials*

Chair Penny A. Asbell

155/ OR26

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	1 ENDPOINTS FOR CLINICAL TRIALS IN DRY EYE DISEASE R.Brazzell, USA (*)		1335.00	2945
0955	2 INNOVATION IN DRY EYE DISEASE: DEWS REPORT P.Asbell, USA (*)		1315.00	2035
1005	3 OSDI IN CLINICAL USE AND THE CLINICALLY MEANINGFUL IMPROVEMENT J.Walt, USA (*)		236.00	9310
1015	4 PROSTAGLANDIN E RECEPTOR SUBTYPE EP3 EXPRESSED IN OCULAR SURFACE EPITHELIUM S.Kinoshita, Japan (*) ; M.Ueta, Japan ; T.Matsuoka, Japan ; S.Narumiya, Japan		1198.00	10981
1025	5 DISCUSSION		240.00	11248
1030	5 COFFEE BREAK		115.00	11248

1100 - 1145

Hall A

*Are There Still Unmet Needs In Treatment Of Glaucoma?**Sponsored By Santen*

Chair Gabor Hollo

160/ SP5

Reference I

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	1 UNMET NEEDS AND EXPECTATIONS IN TOPICAL TREATMENT OF GLAUCOMA G.Hollo, Hungary (*)		1304.00	10951
1115	2 UPDATE ON PROSTAGLANDINS USED FOR GLAUCOMA TREATMENT J.Stjernschantz, Sweden (*)		1306.00	11045
1130	3 THE OCULAR SURFACE IN GLAUCOMA C.Baudouin, France (*)		1317.00	10963

**Saturday 1 March**

1145 - 1230

Hall B

***Nanotechnology***

Chair Christopher A. Paterson

165/ OR28

Time	Title	Poster Board Number	Abstract Number	Reference I
1145	1 DEVELOPING NANOTECHNOLOGY BASED APPROACHES FOR REPAIRING RETINA AND OPTIC NERVE M.De Silva, USA (*)		266.00	10644
1200	2 NANOTECHNOLOGY BASED ADHESIVES FOR CORNEAL WOUND REPAIR M.Grinstaff, USA (*)		1347.00	10646
1215	3 THE IMPACT OF NANOTECHNOLOGY ON EYE TREATMENTS R.Ellis-Behnke, USA (*) ; Y.Liang, China ; D.Tay, China ; K.So, China ; G.Schneider, USA		1174.00	10735
1230	4 LUNCH BREAK		118.00	11248
1230	5 POSTER REVIEWING		308.00	11248

0900 - 1030

Hall C

***Glaucoma Progression - Prevention And Treatment***

Chair Hana Levkovitch-Verbin

170/ OR25

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	1 PRE-PERIMETRIC GLAUCOMA - A CHALLENGE IN DIAGNOSIS AND TREATMENT H.Levkovitch-Verbin, Israel (*)		244.00	10289
0910	2 SELECTIVE LASER TRABECULOPLASTY (SLT) AND ARGON LASER TRABECULOPLASTY (ALT) AS INITIAL THERAPY FOR GLAUCOMA M.Latina (*)		1313.00	10682
0920	3 SELECTIVE LASER TRABECULOPLASTY - WHY DO WE NEED IT? L.Katz, USA (*)		1332.00	11265
0930	4 THE ROLE OF ANTI-VEGF DRUGS IN NEOVASCULAR GLAUCOMA K.Martin, UK (*)		1158.00	9741
0940	5 GLAUCOMA RELATED FINDINGS FROM THE BEIJING EYE STUDY J.Jonas, Germany (*) ; L.Xu, China ; J.Li, China ; H.Yang, China ; S.Wang, China ; Y.Wang, China		1064.00	6697
0950	6 AUTOIMMUNE BIOMARKERS IN GLAUCOMA: NEW THERAPEUTIC TARGETS? F.Grus, Germany (*) ; N.Boehm, Germany ; S.Joachim, Germany ; N.Pfeiffer, Germany		1248.00	9797
0958	7 EFFECTS OF ORAL CYTIDINE-5'-DIPHOSPHOCHOLINE (CITICOLINE) ON RETINAL AND VISUAL EVOKED CORTICAL RESPONSES IN PATIENTS WITH OPTIC NERVE DISEASES V.Parisi, Italy (*) ; F.De Gregorio, Italy ; R.Falchetti, Italy ; C.Barozzi, Italy		1059.00	11064
1006	8 EFFICACY AND SAFETY OF TIMOLOL 0.5 % VS. BRINZOLAMIDE 1% ADDED TO TRAVOPROST 0.004% IN OCULAR HYPERTENSION AND OPEN-ANGLE GLAUCOMA		1018.00	10951

**Saturday 1 March**

0900 - 1030

Hall C

***Glaucoma Progression - Prevention And Treatment***

Chair Hana Levkovitch-Verbin

170/ OR25

Time	Title	Poster Board Number	Abstract Number	Reference
	G.Holló, Hungary (*) ; N.Pfeiffer, Germany			
1014	9 MECHANISM OF ACTION OF LATANOPROST - NEW ASPECTS W.Ulrich, Germany (*) ; A.Moeller, Germany ; C.Ulrich, Germany ; K.Wernecke, Germany ; G.Siebert, Germany		1051.00	10988
1022	10 MORNING DOSED ONCE-DAILY TRAVOPROST/TIMOLOL FIXED COMBINATION COMPARED TO TWICE-DAILY ADMINISTERED DORZOLAMIDE/TIMOLOL IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION A.Fedrigio, Italy (*) ; T.Smoot, USA ; C.Salem, USA ; P.Kothy, Hungary ; G.Hollo, Hungary ; T.Trav/Tim Study Team		1213.00	11158
1030	11 COFFEE BREAK		116.00	11248

1145 - 1230

Hall C

***Antioxidants***

Chair Paul S. Bernstein

175/ OR29

Time	Title	Poster Board Number	Abstract Number	Reference
1145	1 UPDATE ON NUTRITION, DIET, SUPPLEMENTS AND AGE-RELATED MACULAR DEGENERATION J.Seddon, USA (*)		270.00	8790
1200	2 ANTIOXIDANT TARGETING TO PREVENT MITOCHONDRIAL DAMAGE IN RETINAL CELLS M.Boulton, USA (*) ; B.Godley, USA ; H.Lin, USA ; S.Jarrett, USA		1090.00	11049
1215	3 THE MACULAR CAROTENOIDS: BASIC SCIENCE AND CLINICAL STUDIES P.Bernstein, USA (*) ; P.Bhosale, USA		1111.00	3111
1230	4 LUNCH BREAK		119.00	11248
1230	5 POSTER REVIEWING		310.00	11248

1445 - 1545

Hall A

***Treatment For CNV***Chair Baruch D. Kuppermann  
José Cunha-Vaz

180/ OR30

Time	Title	Poster Board Number	Abstract Number	Reference
1445	1 CHARACTERIZATION OF AMD SUBTYPES NEEDED FOR CHOICE OF THERAPY R.Silva, Portugal (*)		354.00	10634
1457	2 LUCENTIS FOR CNV IN AMD G.Staurengi, Italy (*)		362.00	10635
1509	3 INTRAVITREAL BEVACIZUMAB VS. VERTEPORFIN THERAPY PLUS INTRAVITREAL TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 12 MONTHS RESULT S.Michels, Switzerland (*) ; G.Weigert, Austria ; F.Prager, Austria ; S.Sacu, Austria ; A.Varga, Austria ; W.Geitzenauer, Austria ; U.Schmidt-Erfurth, Austria		1056.00	7786

**Saturday 1 March**

1445 - 1545

Hall A

***Treatment For CNV***Chair Baruch D. Kuppermann  
José Cunha-Vaz

180/ OR30

Time	Title	Poster Board Number	Abstract Number	Reference I
1521	4 S.Michels, Switzerland (*) ; G.Weigert, Austria ; F.Prager, Austria ; S.Sacu, Austria ; A.Varga, Austria ; W.Geitzenauer, Austria ; U.Schmidt-Erfurth, Austria MACUGEN FOR CNV - A MAINTENANCE THERAPY M.Tolentino, USA (*) ; A.Berger, USA ; D.Misch, USA ; S.Moon, USA ; R.Hamilton, USA ; M.Espiritu, USA ; M.Goldbaum, USA		1207.00	10673
1533	5 MICRODOSE INTRAVENOUS BEVACIZUMAB TO TREAT RETINA DISEASE E.Thomas, USA (*)		1277.00	9074
1545	6 COFFEE BREAK		120.00	11248

1615 - 1745

Hall A

***Treatment For CNV and Angiogenesis Inhibition - Preclinical Studies***

Chair Arup Das

185/ OR33

Time	Title	Poster Board Number	Abstract Number	Reference I
1615	1 DISTRIBUTION OF ANTI-VEGF ANTIBODIES IN RETINA RPE AND CHOROID IN THE MONKEY AFTER INJECTION INTO THE VITREOUS U.Schraermeyer, Germany (*) ; K.Bartz-Schmidt, Germany ; P.Heiduschka, Germany		1048.00	10642
1625	2 LUCENTIS FOR NON-AMD CNV J.Mones, Spain (*)		326.00	7831
1635	3 IS CYCLOOXYGENASE A RATIONAL THERAPEUTIC TARGET FOR RETINAL ANGIOGENESIS? J.Penn, USA (*) ; S.Yanni, USA ; M.Clark, USA		1160.00	9958
1650	4 NISA NON-PEPTIDE SOMATOSTATIN RECEPTOR AGONISTS SPECIFICALLY TARGETING OCULAR NEOVASCULARIZATION VIA THE SSTR2 RECEPTOR M.Grant, USA (*) ; S.Jurczyk, USA ; S.Palii, USA ; S.Caballero, USA ; R.Miller, USA ; A.Afzal, USA ; G.Shapiro, USA		1086.00	11050
1705	5 STEMMING VISION LOSS WITH STEM CELLS M.Friedlander, USA (*)		1337.00	5063
1720	6 MECHANISMS OF FENRETINIDE (4-HPR) ACTION IN OCULAR ANGIOGENESIS D.Hinton, USA (*) ; R.Kannan, USA		1143.00	11103
1735	7 DISCUSSION		346.00	11248

**Saturday 1 March**

1400 - 1445

Hall B

***Pfizer Sponsored Symposium***

Chair

190/ SP6

Time	Title	Poster Board Number	Abstract Number	Reference I
1	PFIZER ABSTRACTS		256.00	11248

1445 - 1545

Hall B

***My Dilemma In Glaucoma - Case Presentation And Discussion***

Chair Hana Levkovitch-Verbin

195/ OR31

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	1 PANEL: S. MCKINNON, USA, G. HOLLO, HUNGARY, N. GUPTA, CANADA, J.L. KATZ, USA, H. LEVKOVITCH-VERBIN, ISRAEL		271.00	11248
1445	2 UNILATERAL GLAUCOMA IN A YOUNG WOMAN G.Hollo, Hungary (*)		800.00	10951
1500	3 CONTROLLED INTRAOCULAR PRESSURE, UNCONTROLLED DISEASE N.Gupta, Canada (*)		456.00	5477
1515	4 LEAKING BLEB J.Katz, USA (*)		464.00	11265
1530	5 INTERMITTENT LEFT EYE PAIN AND HEADACHE S.McKinnon, USA (*)		789.00	7740
1545	6 COFFEE BREAK		121.00	11248

1615 - 1700

Hall B

***The Nitric Oxide/Carbon Monoxide System: Is It A Tool For New Treatments In Ophthalmology?***

Chair Filippo Drago

200/ OR6

Time	Title	Poster Board Number	Abstract Number	Reference I
1615	1 THE NITRIC OXIDE/CARBON MONOXIDE SYSTEM IN THE EYE C.Bucolo, Italy (*) ; F.Drago, Italy		1278.00	10969
1625	2 HEME OXYGENASE -1 RELATED CARBON MONOXIDE AND FLAVONOIDS IN ISCHEMIC RAT RETINA É.Gallyas, Hungary (*) ; M.Szabó, Hungary ; Á.Tószaki, Hungary		1334.00	11273
1635	3 NITRIC OXIDE (NO) IN THE REGULATION OF INTRAOCULAR PRESSURE J.Maenpaa, Finland (*) ; H.Kotikoski, Finland ; E.Aine, Finland ; P.Alajuuma, Finland ; O.Oksala, Finland ; H.Vapaatalo, Finland		1234.00	11165
1645	4 ROLE OF NITRIC OXIDE IN THE CONTROL OF OCULAR BLOOD FLOW		131.00	8656
1655	6 DISCUSSION		286.00	11248

**Saturday 1 March**

1700 - 1745

Hall B

**Retina Free Papers**

Chair

205/ OR9

Time	Title	Poster Board Number	Abstract Number	Reference I
1700	1 RANIBIZUMAB FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION C.Eandi, Italy (*) ; D.Boeris, Italy ; F.Grignolo, Italy		1270.00	9943
1707	2 RANIBIZUMAB FOR TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION H.Wykrota, Poland ; A.Gierek-Lapinska, Poland ; K.Trzciakowski, Poland (*) ; E.Mrukwa-Kominek, Poland ; A.Pasternak, Poland		1260.00	10568
1714	3 INTRAVITREAL RANIBIZUMAB AFFECTING FELLOW UNTREATED EYE WITH SCAR FORMATION DUE TO EXUDATIVE AGE RELATED MACULAR DEGENERATION A.Rouvas, Greece ; V.Liarakos, Greece (*) ; P.Theodossiadis, Greece ; M.Papathanassiou, Greece ; P.Petrou, Greece ; I.Ladas, Greece ; I.Vergados, Greece		1206.00	11182
1721	4 PHARMACOLOGICAL INHIBITION OF GROWTH HORMONE SECRETION FOR IMPROVEMENT OF EARLY STAGE DIABETIC RETINOPATHY C.Petrou, Greece ; V.Karamanos, Greece ; P.Petrou, Greece (*) ; A.Kofinis, Greece ; A.Archimandritis, Greece		1253.00	11188
1728	5 INTRAVITREAL TRIAMCINOLONE VERSUS BEVACIZUMAB FOR TREATMENT OF REFRACTORY DIABETIC MACULAR EDEMA L.Paccola, Brazil ; R.Costa, Brazil ; M.Folgosa, Brazil ; J.Barbosa, Brazil ; I.Scott, USA ; R.Jorge, Brazil (*)		1190.00	6636
1735	7 ATORVASTATIN FOR DIABETIC MACULAR EDEMA IN DIABETIC PATIENTS WITH ELEVATED SERUM CHOLESTEROL. T.Panagiotoglou, Greece (*) ; E.Ganotakis, Greece ; J.Moschandreass, Greece ; G.Kymionis, Greece ; G.Fanti, Greece ; S.Charisis, Greece ; N.Malliaraki, Greece ; M.Tsilimbaris, Greece		1135.00	11099
1742	7 DISCUSSION		161.00	11248

1445 - 1545

Hall C

**Toxicology**

Chair Frederick Fraunfelder

210/ OR32

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	1 THE NATURE OF TOXIC CATARACT A.LATIES, USA (*)		1082.00	7139
1505	2 OCULAR SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUCTIONS AGENTS F.Fraunfelder, USA (*)		1321.00	11263
1525	3 UPDATE ON OCULAR PHARMACOVIGILENCE		381.00	10730
1545	4 COFFEE BREAK		122.00	11248

**Saturday 1 March**

1615 - 1745

Hall C

**Infection**

Chair Irina Barequet

215/ OR35

Time		Title	Poster Board Number	Abstract Number	Reference I
1615	1	IN VITRO AND IN VIVO SUSCEPTIBILITY - ANTIBIOTIC INTERACTION R.Kowalski, USA (*)		1005.00	10250
1625	2	NEW DEVELOPMENTS FOR ANTIVIRAL AGENTS FOR ADENOVIRUS E.Romanowski, USA (*)		1029.00	10725
1635	3	RESISTANCE TO QUINOLONES: THE RESISTANCE PATTERNS OF NORMAL OCULAR BACTERIAL FLORA TO FLUOROQUINOLONES C.Joo, South Korea (*)		1113.00	10717
1645	4	LONGITUDINAL NATIONWIDE ANTIMICROBIAL SUSCEPTIBILITY SURVEILLANCE IN OCULAR ISOLATES: RESULTS FROM OCULAR TRUST 2 P.Asbell, USA (*) ; D.Sahm, USA		1326.00	2035
1655	5	P. aeruginosa LasA PROTEASE AS A THERAPEUTIC AGENT IN S. AUREUS OCULAR INFECTIONS I.Barequet, Israel (*)		573.00	3024
1705	6	FLUOROQUINOLONE (FQ)-RESISTANT STAPHYLOCOCCUS AUREUS RABBIT ENDOPHTHALMITIS MODEL DEMONSTRATES A 4TH GENERATION FQ PROVIDES MORE EFFECTIVE PROPHYLAXIS THAN A 3RD GENERATION E.Romanowski, USA (*) ; R.Kowalski, USA ; F.Mah, USA ; K.Yates, USA ; H.Sasaki, Japan ; M.Fukuda, Japan ; Y.Gordon, USA		1030.00	10725
1713	7	IN VITRO ACTIVITY OF DIFFERENT TOPICAL OPHTHALMIC ANTIBIOTICS AGAINST PATHOLOGICAL OCULAR MICROBIAL ISOLATES F.Giardini, Italy ; M.Vana, Italy ; U.De Sanctis, Italy ; F.Machetta, Italy ; C.Pollino, Italy ; F.Grignolo, Italy (*)		1062.00	5635
1721	8	CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS ADMITTED WITH KERATITIS IN AN ISRAELI OPHTHALMOLOGY DEPARTMENT F.Lavinsky, Israel (*) ; N.Avni-Zauberman, Israel ; I.Barequet, Israel		1102.00	9916
1729	9	SEVERITY OF KERATITIS IN PATIENTS WITH PREVIOUS PENETRATING KERATOPLASTY, CATARACT SURGERY, OR COMBINED SURGERY F.Lavinsky, Israel (*) ; N.Avni-Zauberman, Israel ; I.Barequet, Israel		1101.00	9916
1737	10	PROPHYLACTIC INTRACAMERAL GENTAMICIN DURING CATARACT SURGERY IN PATIENTS WITH A PENICILLIN ALLERGY M.Issa, UK (*) ; J.Khan, UK ; S.Kandarakis, Greece ; N.Koutroumanos, UK ; M.Qureshi, UK		1107.00	11087

**Sunday 2 March**

0730 - 0900

Hall A

***Clinical Course: Challenging Cases In Glaucoma***

Chair Manfred Zierhut

220/ C5

Time	Title	Poster Board Number	Abstract Number	Reference I
1	CHALLENGING CASES IN GLAUCOMA M.Zierhut, Germany (*)		1163.00	9489
0730	PANEL: H. THIEME, GERMANY, M. ZIERHUT, GERMANY, TBA		233.00	11248

0900 - 1030

Hall A

***Diabetic Retinopathy***Chair Baruch D. Kuppermann  
José Cunha-Vaz

225/ OR37

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	1 VITRASE FOR BITREOUS HEMORRHAGE AND NPDR E.Thomas, USA (*)		369.00	9074
0915	2 SANDOSTATIN LAR D.Boyer, USA (*)		1194.00	2558
0930	3 AVASTIN IN PROLIFERATIVE DIABETIC RETINOPATHY J.Mones, Spain (*)		1336.00	7831
0945	4 ICO-007, A VEGF "+" AGENT FOR THE POTENTIAL TREATMENT OF DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY P.Hnik, Canada (*)		1088.00	10631
1000	5 CONTRIBUTION OF INFLAMMATION TO THE EARLY STAGES OF DIABETIC RETINOPATHY T.Kern, USA (*) ; L.Zheng, USA ; Y.Du, USA		1149.00	10718
1015	6 DISCUSSION		353.00	11248

1100 - 1230

Hall A

***Research And Development For CNV In AMD - Part II***Chair Baruch D. Kuppermann  
José Cunha-Vaz

230/ OR39

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	2 Cand5 siRNA A.Brucker, USA (*)		365.00	3183
1112	2 INTRAOCULAR DELIVERY OF PEGAPTANIB SODIUM WITH SUSTAINED RELEASE MICROSPHERES M.Tolentino, USA (*) ; D.Misch, USA ; A.Berger, USA ; S.Moon, USA ; R.Hamilton, USA ; M.Espiritu, USA ; M.Goldbaum, USA		1276.00	10673
1124	3 TOPICALLY EFFICACIOUS KINASE INHIBITORS IN EXPERIMENTAL MODELS OF LEAK AND ANGIOGENESIS: TG100801, A POTENTIAL TREATMENT FOR POSTERIOR OCULAR DISORDERS R.Soll, USA (*)		1139.00	10733



**Sunday 2 March**

1100 - 1230

Hall A

**Research And Development For CNV In AMD - Part II**Chair Baruch D. Kuppermann  
José Cunha-Vaz

230/ OR39

Time	Title	Poster Board Number	Abstract Number	Reference I
1136	5 NOVEL TOPICAL ANTI-ANGIOGENIC THERAPIES FOR NEOVASCULAR OCULAR DISEASES K.Kengatharan, USA (*)		1294.00	10661
1148	6 SELECTIVE TUBULIN INHIBITORS SHOW EVIDENCE OF ANTIANGIOGENIC AND ANGIOLYTIC EFFECTS IN ANIMAL MODEL OF AMD C.Greven, USA (*) ; F.Lattanzio, USA ; R.English, USA ; A.Hosseini, USA ; P.Williams, USA		1084.00	5625
1200	7 NEW HYPOTHESIS IN THE PATHOGENESIS OF AMD F.Behar-Cohen, France (*) ; C.Feumi, France ; C.Combadiere, France ; R.William, France ; S.Chemtob, France ; S.Sennlaub, France		1153.00	11052
1212	8 RAPAMYCIN (SIROLIMUS) FOR THE TREATMENT OF RETINAL DISEASES A.Laties, USA (*) ; P.Dugel, USA ; D.Kleinman, USA ; J.Haller, USA ; G.Williams, USA ; D.Weber, USA ; M.Blumenkranz, USA		1273.00	7139
1224	9 DISCUSSION		106.00	11248

0900 - 1030

Hall B

**Drug Delivery and Drug Delivery Free Papers**

Chair

235/ OR38

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	1 IONTOPHORESIS INDUCED INTRAOCULAR DELIVERY OF DRUGS J.Frucht-Pery, Israel (*)		1327.00	5074
0910	2 OCULAR PENETRATION OF ORAL FLUOROQUINOLONES IN THE PATIENTS UNDERGOING VITRECTOMY SURGERY A.Ravi, India (*) ; T.Velpandia, India ; N.Biswas, India ; A.Rajpal, India ; S.Garg, India ; S.Ghose, India		1130.00	11096
0917	3 LUCENTIS AND AVASTIN, BUT NOT MACUGEN, SHOW HIGH EFFICIENCY IN NEUTRALIZING VEGF IN A PERFUSION ORGAN CULTURE IN VITRO SYSTE A.Klettner, Germany (*) ; J.Roider, Germany		1137.00	11100
0924	4 AGE AND OCULAR IRRITANCY AS MEASURED WITH IN VITRO BOVINE LENSES J.Sivak, Canada (*) ; L.Ho, Canada ; S.DiCarlo, Canada ; K.Moran, Canada ; V.Bantseev, Canada		1023.00	11027
0931	5 ELECTROPHYSIOLOGICAL EFFECTS OF BRILLIANT BLUE G IN THE MODEL OF THE ISOLATED PERFUSED VERTEBRATE RETINA M.Luke, Germany (*) ; K.Januschowski, Germany ; J.Beutel, Germany ; C.Luke, Germany ; S.Grisanti, Germany ; S.Peters, Germany ; B.Kirchhof, Germany ; K.Bartz-Schmidt, Germany ; P.Szurman, Germany		1028.00	10998
0938	6 SIDE EFFECTS AND PRESCRIPTION ERRORS OF OCULAR DRUGS S.Utman, UK (*) ; A.Specht		1168.00	11133
0945	7 EVALUATION OF THE TRANSCORNEAL PENETRATION AND ANTI-CATARACT POTENTIAL OF A POLYHERBAL FORMULATION(ITONE) N.Biswas, India (*) ; C.Sharma, India ; S.Bandhopadhyaya, India ; T.Velpandian, India ; S.Ghose, India		1021.00	11026
0952	8 PHARMACOTHERAPY OF GLAUCOMA AND ITS INFLUENCE ON TEAR FILM DISTURBANCES		1122.00	11093

**Sunday 2 March**

0900 - 1030

Hall B

**Drug Delivery and Drug Delivery Free Papers**

Chair

235/ OR38

Time	Title	Poster Board Number	Abstract Number	Reference I
0959	9 E.Mrukwa-Kominek, Poland (*) ; S.Gierek-Ciaciura, Poland ; A.Rogowska-Godela, Poland ; A.Pasternak, Poland ; K.Trzci&#261;kowski, Poland ; H.Wykrota, Poland <b>CHITOSAN-BASED COLLOIDAL SYSTEMS AS PROMISING TOPICAL DRUG CARRIERS FOR OCULAR SURFACE DISORDERS</b>		1133.00	4387
1006	10 Y.Diebold, Spain (*) ; L.Contreras-Ruiz, Spain ; A.Lopez-Garcia, Spain ; M.Calonge, Spain ; M.de la Fuente, Spain ; B.Seijo, Spain ; A.Sanchez, Spain ; M.Alonso, Spain <b>INTRAOCULAR IMPLANT OF TRIAMCINOLONE FOR EXTENDED DRUG DELIVERY</b>		1176.00	11010
1013	11 P.Mora, Italy (*) ; U.Ceglarek, Germany ; F.Manzotti, Italy ; J.Orsoni, Italy <b>CYCLOSPORIN A IN THE OCULAR FLUIDS OF UVEITIS PATIENTS FOLLOWING LONG-TERM SYSTEMIC ADMINISTRATION</b>		1187.00	11156
1020	12 L.Arrico, Italy (*) ; F.De Gregorio, Italy ; S.Donati, Italy ; L.Colao, Italy ; N.Iozzo, Italy <b>ANALYSIS BY CORNEAL CONFOCAL MICROSCOPY (CS3) ON THE EFFECTS OF LONG-TERM TOPICAL DORZOLAMIDE THERAPY</b>		1123.00	2184
1027	13 <b>DISCUSSION</b>		201.00	11248
1030	14 <b>COFFEE BREAK</b>		367.00	11248

1100 - 1145

Hall B

**Anterior Segment Free Papers**

Chair

240/ OR40

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	1 Z.Valyi, Spain (*) ; A.Mateo, Spain ; J.Ibanez, Spain ; D.Perez, Spain ; N.Lafuente, Spain ; J.Cristobal, Spain ; M.Rojo, Spain <b>EVALUATION OF PTERYGIUM SURGERY: THE USE OF FIBRIN ADHESIVE FOR ATTACHING CONJUNCTIVAL AUTOGRAFT</b>		1256.00	11210
1107	2 S.Srinivas, USA (*) ; S.Mahesh, USA <b>DIFFERENTIAL MODULATION OF ACTIN CYTOSKELETON DURING THE BREAKDOWN OF BARRIER INTEGRITY OF CORNEAL ENDOTHELIAL CELLS BY THROMBIN AND TNF-ALPHA</b>		1241.00	11200
1114	3 V.Liarakos, Greece (*) ; M.Papathanassiou, Greece ; P.Theodossiadis, Greece ; A.Rouvas, Greece ; M.Douvali, Greece ; E.Papastergiopoulou, Greece ; I.Vergados, Greece <b>INHIBITORY EFFECT OF ANTI-VEGF AGENTS ON CORNEAL NEOVASCULARIZATION</b>		1205.00	11182
1121	4 S.Gupta, India (*) ; V.Kalai Selvan, India ; S.Srivastava, India ; N.Galpalli, India ; R.Agarwal, India ; S.Agrawal, India ; R.Saxena, India <b>POTENTIAL OF TRADITIONAL AYURVEDIC DRUG - TRIGONELLA FOENUM - AS A NOVEL ANTI CATARACT AGENT</b>		1191.00	11175
1128	5 M.Rolando, Italy (*) ; C.Barozzi, Italy ; R.Falchetti, Italy ; F.De Gregorio, Italy <b>CLINICAL EFFICACY AND TOLERABILITY OF A PHOSPHOLIPID BASED MICROEMULSION IN OCULAR SURFACE DISORDERS</b>		1060.00	9787
1135	6 V.Fokin, Russia ; L.Boriskina, Russia (*) ; L.Ushakova, Russia <b>OZONE THERAPY IN COMPREHENSIVE TREATMENT OF CORNEAL STROMAL DYSTROPHY</b>		1057.00	11062

**Sunday 2 March**

1100 - 1145

Hall B

***Anterior Segment Free Papers***

Chair

240/ OR40

Time	Title	Poster Board Number	Abstract Number	Reference
1143	7 DISCUSSION			11248
			107.00	

1145 - 1230

Hall B

***Retina Free Papers***

Chair

245/ OR41

Time	Title	Poster Board Number	Abstract Number	Reference
1145	1 INIBITION OF VEGF SECRETION AND EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION BY PICROPODOPHYLLIN (PPP), AN INHIBITOR OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) M.Economou, Sweden (*); J.Wu, Sweden; D.Vasilcanu, Sweden; L.Rosengren, Sweden; C.All-Ericsson, Sweden; L.Girmita, Sweden; M.Axelsson, Sweden; O.Larsson, Sweden; S.Seregard, Sweden; A.Kvanta, Sweden		1080.00	4
1152	2 ANTI-ANGIOGENIC VEGF165B IS NEUROPROTECTIVE IN RAT OCULAR ISCHEMIC-INJURY MODEL J.Hua, UK (*); T.Jehle, Germany; R.Dersch, Germany; A.Churchill, UK; S.Harper, UK; W.Lagrèze, Germany; D.Bates, UK		1077.00	11004
1158	3 ANTI-PLGF AS AN ALTERNATIVE OR SUPPLEMENT TO ANTI-VEGF THERAPY FOR SUPPRESSING CHOROIDAL NEOVASCULARIZATION (CNV) AND MACULAR EDEMA S.Vinorens, Belgium (*); S.Van de Veire, Belgium; L.Moons, Belgium; I.Stalmans, Belgium; D.Collen, Belgium; P.Carmeliet, Belgium		1058.00	11063
1204	5 CCR3 IS A SPECIFIC NEOVASCULAR TARGET IN AGE-RELATED MACULAR DEGENERATION J.Baffi, USA (*); A.Takeda, USA; M.Noizaki, USA; K.Yamada, USA; M.Kleinman, USA; R.Albuquerque, USA; B.Raisler, USA; B.Ambati, USA; A.Humbles, USA; C.Gerard, USA; P.Geisen, USA; M.Hartnett, USA; S.Grisanti, Germany; M.Rothenberg, USA; J.Ambati, USA		1010.00	10714
1210	5 THE EFFECT OF INTRAVITREAL INJECTION OF KETOROLAC TROMETHAMINE IN POSTOPERATIVE CYSTOID MACULAR EDEMA M.Tsilimbaris, Greece (*); T.Panagiotoglou, Greece; V.Panteleontidis, Greece; C.Tsika, Greece		1136.00	9795
1216	6 CHOROIDAL BLOOD FLOW CHANGES DURING LIGHT/DARK TRANSITIONS ARE DEPENDENT ON THE DOPAMINE SYSTEM G.Fuchsjaeger-Mayrl, Austria (*); K.Huemer, Austria; B.Pemp, Austria; G.Weigert, Austria; H.Resch, Austria; G.Garhofer, Austria; L.Schmetterer, Austria		1115.00	10176
1222	7 DISCUSSION			11248
			163.00	

**Friday 29 February**

1315 - 1400

Poster Area

**Poster Session 1**

Chair

300/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference I
0	IN VITRO STUDY ON RECONSTITUTED HUMAN CORNEAL EPITHELIUM OF THE HEALING ADJUVANT EFFICACY AND INFLAMMATORY/PRO-FIBROTIC POTENTIAL OF DIFFERENT TEAR SUBSTITUTES M.Meloni, Italy (*) ; B.De Servi, Italy ; F.De Gregorio, Italy ; C.Barozzi, Italy ; R.Falchetti, Italy		1061.00	11065
0	EFFECT OF TOPICAL DA-6034 APPLICATION ON DRY EYE SYNDROME ANIMAL MODELS S.Choi, South Korea (*) ; M.Seo, South Korea ; Y.Lee, South Korea ; Y.Sohn, South Korea ; K.Kang, South Korea ; B.Ahn, South Korea		1073.00	11072
0	THE EFFECT OF FRESH ALOE VERA GEL ON THE INTRAOCULAR PRESSURE OF EXPERIMENTAL RABBIT EYES C.Asonye, Nigeria (*) ; G.Agu, Nigeria ; P.Diji, Nigeria		1220.00	11187
0	EFFECTIVENESS OF BRILLIANT BLUE G FOR CAPSULAR STAINING FOR CONTINUOUS CURVILINEAR CAPSULORHEXIS M.Diaz-Llopis, Spain (*) ; S.Udaondo, Spain ; S.Garcia-Delpech, Spain ; D.Salom, Spain ; J.Romero, Spain ; F.Bosch, Spain		1264.00	11213
0	OCULAR TOLERABILITY OF PRESERVATIVES IN EYE DROPS J.Kameni Tcheudji, Switzerland (*) ; J.Bizec, Switzerland		1197.00	3140
0	POWERFUL AND WELL-TOLERATED NEW OPHTHALMIC PRESERVATIVES - SPECIFIC USE OF QUATERNARY AMMONIUM CYCLODEXTRINES G.Kis, Switzerland (*) ; J.Bizec, Switzerland		1209.00	11167
0	CATARACTOGENIC RISKS OF GLYPHOSATE (HERBICIDE) EXPOSURE - THE BIOCHEMICAL MECHANISM AND PROBABLE MODEL OF ANTIOXIDANT REMEDIATION C.Asonye, Nigeria (*) ; E.Nwanze, Nigeria		1216.00	11185
0	SEVERE OPTIC NEUROPATHY CAUSED BY DICHLOROMETHANE INHALATION - CASE REPORT A.Ando, Japan (*) ; A.Kobayashi, Japan ; N.Tagami, Japan ; M.Kitagawa, Japan ; E.Kawai, Japan ; M.Akioka, Japan ; E.Arai, Japan ; T.Nakatani, Japan ; Y.Matsui, Japan ; M.Matsumura, Japan		1183.00	11008
0	REDUCTION OF QUATERNARY AMMONIUM-INDUCED OCULAR SURFACE TOXICITY BY EMULSIONS: AN IN VIVO STUDY IN RABBITS H.Liang, France (*) ; F.Brignole-Baudouin, France ; L.Rabinovich-Guilatt, France ; M.Faure, France ; J.Warnet, France ; G.Lambert, France ; C.Baudouin, France		1038.00	11031
0	ENHANCED CORNEAL EPITHELIUM HEALING BY LIPIMIX TREATMENT IN A RABBIT MODEL A.Solomon, Israel (*) ; N.Savion, Israel		1196.00	11178
0	CONSIDERATIONS ON THE RISKS OF PRECIPITATION OF CALCIUM PHOSPHATE SALTS FOLLOWING THE USE OF VISMED (0.18% SODIUM HYALURONATE) FORMULATION D.Aleo, Italy ; L.Bossy, Switzerland (*)		1240.00	9731
0	PHYSICO-CHEMICAL CHARACTERIZATION AND PRECLINICAL STUDIES OF A NEW SOLUTION OF MELOXICAM FOR OPHTHALMIC APPLICATION J.Quintana-Hau, Mexico (*) ; L.Baiza-Duran, Mexico ; R.Mondragon-Flores, Mexico ; C.Cortes-Alvarez, Mexico ; J.Tornero-Montano, Mexico		1045.00	10950
0	ESTIMATION OF LUTEIN, LYCOPENE AND BETA-CAROTENE LEVELS IN THE FRUITS AND VEGETABLES S.Ghose, India (*) ; C.Gayathri, India ; T.Velpandian, India		1128.00	5550

**Friday 29 February**

1315 - 1400

Poster Area

**Poster Session 1**

Chair

300/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference I
0	EFFECT OF IONTOPHORESIS ON THE IN-VITRO TRANSSCLERAL TRANSPORT OF HIGH MOLECULAR WEIGHT NEUTRAL COMPOUNDS S.Nicoli, Italy (*) ; G.Ferrari, Italy ; M.Quarta, Italy ; P.Govoni, Italy ; P.Santi, Italy		1065.00	11068
0	A SURVEY OF OCULAR DRUG AND DIAGNOSTIC PATENTING, OCTOBER 2005 TO SEPTEMBER 2007 H.Mucke, Austria (*) ; E.Mucke, Austria		1089.00	9669
0	A NOVEL PRODRUG OF ESTRADIOL PROTECTS THE RETINA IN A RAT MODEL FOR GLAUCOMA UPON TOPICAL ADMINISTRATION K.Prokai-Tatrai, USA (*) ; H.Xin, USA ; V.Nguyen, USA ; P.Koulen, USA ; L.Prokai, USA		1104.00	8
0	NOVEL FORMULATION OF AN OCULAR HYPOTENSIVE MELATONIN MT3 RECEPTOR AGONIST (5-MCA-NAT) V.Andres-Guerrero, Spain ; P.Alarma-Estrany, Spain ; A.Peral, Spain ; M.Vicario, Spain ; D.Barbosa, Spain ; J.Pintor, Spain ; R.Herrero-Vanrell, Spain (*)		1121.00	5941
0	GDNF-LOADED PLGA MICROPARTICLES FOR INTRAVITREOUS ADMINISTRATION. EFFECT OF BSA ON THE IN-VITRO RELEASE P.Checa-Casalengua, Spain ; I.Bravo-Osuna, Spain ; S.Sacristan, Spain ; I.Molina-Martinez, Spain ; M.Young, USA ; R.Herrero-Vanrell, Spain (*)		1129.00	5941
0	THE PRELIMINARY IN VITRO RELEASE PROFILE EVALUATION OF INTRAOCULAR BIODEGRADABLE IMPLANTS CONTAINING CYCLOSPORINE A FOR THE TREATMENT OF POSTERIOR UVEITIS J.Saliba, Brazil ; M.Yoshida, Brazil ; A.Faraco, Brazil ; H.Mansur, Brazil ; A.Cunha, Brazil (*)		1131.00	11097
0	CATARACT RISK REDUCTION IN DIABETIC PATIENTS USING METFORMIN COMPARISON TO GLIBEN CLAMIDE A.Pourvali, Iran ; K.Kiyani Peykani, Iran (*)		1177.00	11303
0	LOCAL ANESTHETICS USED IN OPHTHALMIC PRACTICE L.Balashovich, Russia (*) ; E.Somov, Russia		1188.00	11174
0	OCULAR PERMEATION ENHANCERS FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS G.Kis, Switzerland (*) ; C.Schoch, Switzerland		1208.00	11167
0	NEW AMPHIPHILIC POLY(HYDROXYETHYL)ASPARTAMIDE DERIVATIVES FOR OCULAR DELIVERY C.Civiale, Italy (*) ; M.Licciardi, Italy ; G.Giammona, Italy ; M.Mazzone, Italy		1245.00	11204
0	IMPACT OF P-GLYCOPROTEIN (P-GP) DRUG EFFLUX TRANSPORTER BLOCKADE ON THE SYSTEMIC AND OCULAR DISPOSITION OF P-GP SUBSTRATE S.Kumari, India (*) ; T.Velpandian, India ; N.Biswas, India ; N.Sonali, India ; S.Ghose, India		1126.00	11095
0	CORRELATION OF MOLECULAR PROPERTIES WITH THE INTRA OCULAR PENETRATION OF FLUOROQUINOLONES IN EXPERIMENTAL STUDIES T.Velpandian, India (*)		1125.00	11094
0	RETINAL PIGMENT EPITHELIAL CELL (RPE) GROWTH AND FUNCTION ON SURFACE MODIFIED EXPANDED POLYTETRAFLUOROETHYLENE: A POTENTIAL SUBSTRATE FOR TRANSPLANTATION C.Sheridan, UK (*) ; Y.Krishna, UK ; D.Kent, UK ; R.Williams, UK ; I.Grierson, UK		1268.00	11214

**Friday 29 February**

1315 - 1400

Poster Area

**Poster Session 1**

Chair

300/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference I
0	TIMECOURSE OF PROTECTIVE EFFECT OF SAFFRON IN LIGHT-INDUCED DAMAGE R.Maccarone, Italy (*) ; S.Di Marco, Italy ; J.Fisher, Australia ; C.Salmon, Australia ; S.Bisti, Italy ; K.Valter, Australia		1238.00	11199
0	VALUE OF NEAR-INFRARED TREATMENT IN RETINAL DEGENERATION K.Valter, Australia (*) ; D.Kirk, Australia ; J.Stone, Australia ; J.Eells, USA		1237.00	11198
0	THE EFFECTS OF BEVACIZMAB AND RANIBIZUMAB ON PERMEABILITY OF CULTURED RPE Y.Miura, Germany (*) ; A.Klettner, Germany ; J.Roeder, Germany		1134.00	11098
0	NEUROPROTECTIVE EFFECT OF BRIMONIDINE IN A MOUSE MODEL OF ISCHEMIC OPTIC NEUROPATHY S.Dadon, Israel (*) ; M.Hasanreisoglu, Israel ; B.Avraham, Israel ; D.Weinberger, Israel ; N.Goldenberg-Cohen, Israel		1097.00	11083
0	MISREGULATION OF RHODOPSIN PHOSPHORYLATION AND DEPHOSPHORYLATION IS A COMMON MECHANISM IN P23H AND S334TER RETINAL DEGENERATION H.Ohguro, Japan (*) ; I.Ohguro, Japan		1092.00	11080
0	GANODERM LUCIDUM SPORES OIL PROMOTE RETINAL VEGF EXPRESSION IN THE RAT ANIMAL MODEL OF THE PHOTORECEPTOR DAMAGE INDUCED BY MNU X.Deng, China (*) ; J.Ge, China ; Y.Gao, China ; Z.Zhong, China		1055.00	4372
0	RETINAL VEIN OCCLUSION IN PIGS AS A MODEL OF ACUTE RETINAL EDEMA M.Paques, France (*) ; M.Simonutti, France ; B.El-Mathari, France ; D.Pruneau, France ; J.Sahel, France		1203.00	11180
0	INFLUENCE OF CAFFEINE ON VASCULAR AUTOREGULATIVE RESPONSIVENESS IS MEASURABLE BY RETINAL DVA M.Kneser, Germany (*) ; J.Pokorny, Germany ; F.Tost, Germany		1141.00	10259
0	CIRCULATORY PARAMETERS IN THE RETROBULBAR CENTRAL RETINAL ARTERY AND VEIN OF PATIENTS WITH DIABETES AND MEDICALLY TREATED SYSTEMIC HYPERTENSION G.Dimitrova, Macedonia (*) ; S.Kato, Japan ; H.Fukushima, Japan ; H.Yamashita, Japan		1070.00	11070
0	REVERSIBLE ENHANCEMENT OF RPE PERMEABILITY BY PLACENTAL GROWTH FACTOR: IMPLICATIONS FOR DRUG DELIVERY TO THE RETINA M.Abdulrazik, France (*) ; N.Miyamoto, France ; F.Behar-Cohen, France		1222.00	11189
0	EFFECT OF Î-LIPOIC ACID ON ELECTRORETINOGRAPHIC CHANGES IN EARLY EXPERIMENTAL DIABETIC RETINOPATHY M.Garcia-Pous, Spain (*) ; M.Diaz Llopis, Spain ; S.Garcia-Delpech, Spain ; F.Bosch Morell, Spain ; J.Romero Gomez, Spain ; S.Soriano, Spain ; D.Salom Alonso, Spain ; P.Udaondo Mirete, Spain ; B.Moratal Peiro, Spain		1204.00	11181
0	INTRAVITREAL RANIBIZUMAB (LUCENTIS) AS INITIAL TREATMENT FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH VARIOUS CAUSES D.Dardabounis, Greece (*) ; I.Perente, Greece ; K.Ioannakis, Greece ; E.Alvanos, Greece ; S.Koukoulas, Greece ; X.Yfantis, Greece ; E.Kalogianni, Greece ; V.Kozobolis, Greece		1254.00	11209
0	DEVELOPMENT OF COLLATERAL VESSELS UNDER AVASTIN® THERAPY FOR BRANCH RETINAL VEIN OCCLUSION J.Schmidt, Germany (*) ; S.Mennel, Germany ; C.Meyer, Germany ; C.Hoerle, Germany		1244.00	11203

## Friday 29 February

1315 - 1400

Poster Area

## Poster Session 1

Chair

300/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference I
0	PEGAPTANIB SODIUM IN TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION: ONE-YEAR RESULTS H.Wykrota, Poland ; K.Trzciakowski, Poland (*) ; U.Gajdzik-Gajdecka, Poland ; E.Mrukwa, Poland ; A.Pasternak, Poland		1262.00	10568
0	EFFECTS OF BEVACUZIMAB (AVASTIN) ON DIABETIC MACULAR EDEMA IN CASES WITH PROLIFERATIVE DIABETIC RETINOPATHY L.Ceklic, Bosnia-Herzegovina (*) ; S.Latinovic, Serbia		1185.00	11152
0	INTRAVITREAL BEVACIZUMAB FOR VITREOUS HEMORRHAGE S.von Baltz, Germany (*) ; T.Libondi, Italy ; U.Vossmerbaeumer, Germany ; J.Jonas, Germany		1275.00	11013
0	INTRAVITREAL BEVACIZUMAB VERSUS TRIAMCINOLONE ACETONIDE FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION S.von Baltz, Germany (*) ; J.Jonas, Germany ; A.Ihloff, Germany ; B.Harder, Germany ; I.Kreissig, Germany ; F.Schlichtenbrede, Germany ; T.Libondi, Italy ; U.Spandau, Germany		1274.00	11013
0	INTRAVITREAL PEGAPTANIB SODIUM FOR REFRACTORY MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION D.Salom, Spain (*) ; S.Garcia-Delpech, Spain ; P.Udaondo, Spain ; Q.Cervera, Spain ; M.Diaz-Llopis, Spain ; M.Garcia-Pous		1266.00	11213
0	INTRAVITREAL PEGAPTANIB INJECTION AS A TREATMENT FOR REFRACTORY PSEUDOPHAKIC CYSTOID MACULAR EDEMA E.Cervera, Spain (*) ; D.Salom, Spain ; P.Udaondo, Spain ; S.Garcia-Delpech, Spain ; M.Diaz-Llopis, Spain		1265.00	11213
0	SPONTANEOUS RESOLUTION OF VITREOMACULAR TRACTION FOLLOWING RANIBIZUMAB (LUCENTIS) INJECTION A.Rouvas, Greece ; P.Petrou, Greece (*) ; I.Ladas, Greece ; G.Neamonitou, Greece ; V.Liarakos, Greece ; I.Vergados, Greece		1221.00	11188
0	EFFECTS OF CEO2 (CERIUM OXIDE) NANOPARTICLES ON RETINAL STRESS IN ANIMAL MODEL S.Bisti, Italy (*) ; R.Maccarone, Italy ; S.Di Marco, Italy ; S.Romeo, Italy ; M.Passacantando, Italy ; A.Phani, Italy ; S.Santucci, Italy		1249.00	2715
0	INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - ONE YEAR EXPERIENCE D.Risimic, Serbia (*) ; V.Jaksic, Serbia ; M.Stojkovic, Serbia ; S.Milenkovic, Serbia ; N.Jakovic, Serbia ; L.Ivankovic, Serbia ; B.Kalezic, Serbia ; T.Kalezic, Serbia ; J.Djukic, Serbia		1246.00	11205
0	COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIRIN AND INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ALL TYPES OF CHOROIDAL NEOVASCULARISATION DUE TO AGE-RELATED MACULAR DEGENERATION I.Jankowska-Lech, Poland (*) ; I.Liberek, Poland ; A.Jamrozy-Witkowska, Poland ; B.Terelak-Borys, Poland ; A.Wójcik, Poland		1239.00	11127
0	NEUROPROTECTIVE THERAPY IN ISCHEMIC OPTIC NEUROPATHY M.Shahsuvaryan, Armenia (*)		1228.00	11194
0	BEVACIZUMAB AND PHOTODYNAMIC THERAPY TO TREAT JUXTAPAPILLARY CAPILLARY HEMANGIOMA S.Mennel, Germany (*) ; J.Callizo, Germany ; J.Schmidt, Germany		1217.00	7764
0	EVALUATION OF MACULAR PIGMENT OPTICAL DENSITY (MPOD) IN PATIENTS WITH AMD C.Tsika Chrysanthi, Greece (*) ; G.Kontadakis, Greece ; M.Makridaki, UK ; M.Tsilimbaris, Greece		1210.00	11183

**Friday 29 February**

1315 - 1400

Poster Area

**Poster Session 1**

Chair

300/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference I
0	SIMVASTATIN AND ASPECARD EFFECT ON THE THRESHOLD RETINAL SENSITIVITY IN PATIENTS WITH NONEXUDATIVE FORM OF AGE-RELATED MACULAR DEGENERATION M.Karliychuk, Ukraine (*) ; S.Pinchuk, Ukraine ; M.Zubovych, Ukraine		1200.00	11179
0	PARS PLANA VITRECTOMY FOR TREATMENT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE INDUCED-HERPETIC KERATITIS REFRACTORY TO THERAPY D.Guven, Turkey (*) ; E.Kucuk, Turkey ; D.Kalayci, Turkey ; H.Hasiripi, Turkey		1145.00	11105
0	EARLY CHANGES OF CENTRAL RETINAL SENSITIVITY FOLLOWING INTRAVITREAL INJECTION OF TRIAMCINOLONE ACETONIDE FOR DIABETIC MACULAR EDEMA T.Kameda, Japan (*) ; K.Nishijima, Japan ; H.Oh, Japan ; N.Unoki, Japan ; A.Sakamoto, Japan ; H.Hayashi, Japan ; M.Kita, Japan ; N.Yoshimura, Japan		1114.00	11040
0	ENLARGEMENT OF ONCE-INACTIVATED POLYPOIDAL VASCULOPATHY BY PHOTODYNAMIC THERAPY H.Tamura, Japan (*) ; A.Tsujikawa, Japan ; A.Otani, Japan ; Y.Yodoi, Japan ; T.Kameda, Japan ; N.Yoshimura, Japan		1112.00	11090
0	PHOTODYNAMIC THERAPY FOR THE TREATMENT OF CORNEAL AND RETINAL DISEASES IN CHILDREN M.Fortunato, Italy (*) ; R.Maggi, Italy ; P.Vadala', Italy		1105.00	5041
0	FREQUENCY OF VISUAL EVOKED POTENTIAL RESPONSE ABNORMALITIES IN 25 DIABETIC RETINOPATHY PATIENTS IN MASHHAD M.shaygan, Iran (*) ; M.homam, Iran ; N.chaichi tehrani, Iran		1098.00	11084
0	CENTRAL RETINAL SENSITIVITY MEASURED WITH THE MICRO PERIMETER 1 AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION Y.Yodoi, Japan (*) ; A.Tsujikawa, Japan ; H.Tamura, Japan ; H.Hayashi, Japan ; T.Kameda, Japan ; Y.Ojima, Japan ; H.Nakanishi, Japan ; A.Otani, Japan ; N.Yoshimura, Japan		1074.00	11061
0	TREATMENT OF THE CHRONIC CENTRAL SEROUS CHORIORETHINOPATHY BY PHOTODYNAMIC THERAPY F.Erdurman, Turkey (*) ; A.Durukan, Turkey ; T.Mumcuoglu, Turkey ; M.Bayraktar, Turkey		1013.00	11025
0	EARLY INTRAVITREAL BEVACIZUMAB FOR NON-ISCHEMIC BRANCH RETINAL VEIN OCCLUSION F.Rensch, Germany (*) ; U.Spandau, Germany ; J.Jonas, Germany		1008.00	10955
0	INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION F.Rensch, Germany (*) ; U.Spandau, Germany ; S.von Baltz, Germany ; T.Libondi, Germany ; U.Voßmerbäumer, Germany ; J.Jonas, Germany		1007.00	10955
0	EARLY INTRAVITREAL BEVACIZUMAB FOR NON-ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION F.Rensch, Germany (*) ; U.Spandau, Germany ; J.Jonas, Germany		1006.00	10955
0	THE EFFECT OF RETINAL AGE PIGMENT, A2E ON CHOROIDAL NEOVASCULARIZATION Y.Tamaki, Japan (*) ; A.Iriyama, Japan ; Y.Yanagi, Japan		1117.00	1757
0	THE EXPRESSION OF RETINOTOXIC EFFECTS OF INTRAVITREAL KENALOG: RABBITS VERSUS HUMAN PATIENTS		1014.00	10729



# Friday 29 February

1315 - 1400

Poster Area

## Poster Session 1

Chair

300/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference I
	Y.Lang, Israel (*) ; E.Zemel, Israel ; B.Miller, Israel ; N.Shoham, Israel ; R.Leibu, Israel ; I.Perlman, Israel			
0	PHOTODYNAMIC THERAPY WITH RIBOFLAVIN AS AN ALTERNATIVE METHOD FOR AGE-RELATED MACULAR DEGENERATION R.Ion, Romania (*) ; M.Ionita, USA ; B.Carstocea, Romania		1302.00	11257

**Saturday 1 March**

1315 - 1400

Poster Area

**Poster Session II**

Chair

350/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference I
0	EFFECT OF VASOPRESSIN V1 RECEPTOR ANTAGONIST ON OPTIC NERVE BLOOD FLOW AUTOREGULATION IN EXPERIMENTAL ISCHEMIC OPTIC NEUROPATHY S.Gokce, Turkey (*) ; G.Haciyakupoglu, Turkey ; S.Zorludemir, Turkey ; S.Polat, Turkey ; K.Aksoy, Turkey ; S.Menziletoglu, Turkey ; K.Daglioglu, Turkey		1025.00	11028
0	CO-TREATMENT OF SUBEROYLANILIDE HYDROXAMIC ACID AND MITOMYCIN-C INDUCES THE APOPTOSIS OF RABBIT TENON'S CAPSULE FIBROBLAST AND IMPROVES OUTCOME OF TRABECULECTOMY J.Woo, South Korea (*) ; S.Kim, South Korea ; J.Seo, South Korea ; J.Rho, South Korea ; Y.Yoo, South Korea ; S.Rho, South Korea		1046.00	11057
0	OUTCOME FIVE YEARS AFTER GONIOCURETTAGE COMBINED WITH PHACOEMULSIFICATION FOR GLAUCOMA H.Hayashi, Japan (*) ; Y.Tsukahara, Japan ; Y.Kurimoto, Japan ; Y.Ueda, Japan		1040.00	11054
0	INTRAOCULAR PRESSURE REDUCTION BY LATANOPROST FOR NORMAL TENSION GLAUCOMA: RESULTS OVER FIVE YEARS COMPARED BETWEEN HIGH-TENSION AND LOW-TENSION JAPANESE PATIENTS M.Tsuda, Japan (*) ; A.Ando, Japan ; C.Fukui, Japan ; K.Matsuyama, Japan ; A.Kuwahara, Japan ; T.Nishimura, Japan ; H.Nambu, Japan ; M.Matsumura, Japan		1184.00	11053
0	IS THERE CORRELATION BETWEEN BLOOD PRESSURE AND INTRAOCULAR PRESSURE? AN EXPERIMENTAL STUDY IN HYPERTENSIVE RATS A.Vaajanen, Finland (*) ; E.Mervaala, Finland ; O.Oksala, Finland ; H.Vapaatalo, Finland		1031.00	10184
0	IN VITRO TOXICITY OF PRESERVATIVE-FREE TAFLUPROST AND PRESERVED LATANOPROST, TRAVOPROST AND BIMATOPROST: A STUDY ON CONJUNCTIVAL EPITHELIAL CELLS E.Brasnu, France ; H.Liang, France ; F.Brignole-Baudouin, France ; L.Riancho, France ; J.Guenoun, France ; J.Warnet, France ; C.Baudouin, France (*)		1124.00	10963
0	BEVACIZUMAB + EX-PRESS VALVE IMPLANT FOR THE TREATMENT OF NEOVASCULAR GLAUCOMA: A PILOT STUDY T.Micelli Ferrari, Italy (*) ; M.Leozappa, Italy ; V.Pace, Italy ; A.Catalano, Italy		1041.00	11055
0	PATHOLOGICAL CARDIOVASCULAR FUNCTION IN EXFOLIATION SYNDROME Z.Visontai, Hungary (*) ; T.Horvath, Hungary ; B.Mersich, Hungary ; M.Kollai, Hungary ; G.Hollo, Hungary		1016.00	10921
0	THE EFFICACY OF LATANOPROST ON REPRODUCED 24 HOUR IOP CHANGE T.Hara, Japan (*) ; M.Narita, Japan ; T.Hashimoto, Japan		1255.00	11086
0	COMPARATIVE EFFECTS OF SELECTED ANTI-CHOLINERGIC AGENTS ON INTRA-OCULAR PRESSURE (IOP) IN RABBITS G.Sadeghi Hashjin, Iran (*) ; H.Manokzadeh, Iran		1012.00	11024
0	FREQUENCY OF HLA-DR EXPRESSION IN CONJUNCTIVAL CELLS AFTER TOPICAL ANTIGLAUCOMA TREATMENT DISCONTINUANCE M.Veronese Rodrigues, Brazil (*) ; D.Felipe Crosta, Brazil ; E.Soaes, Brazil ; E.Donadi, Brazil ; R.Duarte, Brazil ; N.Deghaide, Brazil ; J.Furtado, Brazil ; J.Paula, Brazil ; E.Rocha, Brazil ; C.Soaes, Brazil		1106.00	10992
0	PROGRESSION OF GLAUCOMA UNDER TREATMENT: CAN SCANNING LASER POLARIMETRY BE USED FOR MONITORING THE PATIENTS? M.Toth, Hungary (*) ; G.Hollo, Hungary		1020.00	11001
0	EFFECTS OF INTRAVITREAL BEVACIZUMAB ON NEOVASCULAR GLAUCOMA E.Kirii, Japan (*) ; T.Yamamoto, Japan ; M.Nagasawa, Japan ; N.Mochizuki, Japan ; S.Nakano, Japan ; H.Yamashita, Japan		1108.00	11006

**Saturday 1 March**

1315 - 1400

Poster Area

**Poster Session II**

Chair

350/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference I
	E.Kirii, Japan (*) ; T.Yamamoto, Japan ; M.Nagasawa, Japan ; N.Mochizuki, Japan ; S.Nakano, Japan ; H.Yamashita, Japan			
0	COST-EFFECTIVENESS OF FIXED COMBINATION THERAPIES GANFORTÂ®, DUOTRAVÂ® AND XALACOMÂ® IN EUROPEAN COUNTRIES		1172.00	6057
	A.Hommer, Austria (*) ; M.Friis, Denmark ; J.Wickstrom, Denmark ; P.Poulsen, Denmark ; J.Walt, USA ; P.Buchholz, Germany			
0	COMPARISON OF THE DIURNAL INTRAOCULAR PRESSURE-LOWERING EFFICACY OF BIMATOPROST 0.03%, LATANOPROST 0.005% AND TRAVOPROST 0.004% IN PATIENTS WITH GLAUCOMA.		1015.00	11022
	A.Ferreras, Spain (*) ; A.Pajarin, Spain ; L.Pablo, Spain ; J.Larrosa, Spain ; V.Polo, Spain			
0	EFFECT ON INTRAOCULAR PRESSURE ACHIEVED WITH BIMATOPROST IN GLAUCOMA PATIENTS PREVIOUSLY TREATED WITH THE FIXED-COMBINATION OF LATANOPROST AND TIMOLOL		1009.00	11022
	A.Ferreras, Spain (*) ; A.Pajarin, Spain ; V.Polo, Spain ; J.Larrosa, Spain			
0	CAN SELECTIVE LASER TRABECULOPLASTY SUBSTITUTE MEDICAL THERAPY OF PRIMARY OPEN-ANGLE GLAUCOMA?		1017.00	10937
	P.Kothy, Hungary (*) ; M.Toth, Hungary ; G.Hollo, Hungary			
0	EFFECT OF ANTHOCYANINS IN BLACK CURRANT ON RETINAL BLOOD CIRCULATION OF PATIENTS WITH NORMAL TENSION GLAUCOMA.		1093.00	11081
	I.Ohguro, Japan (*) ; H.Ohguro, Japan			
0	DEEP LID SULCUS AND BLEPHAROPTOSIS AFTER TREATMENT WITH TOPICAL TRAVOPROST AND BIMATOPROST		1230.00	11195
	S.Ha, South Korea (*) ; H.Sun, South Korea ; S.Park, South Korea			
0	EFFICACY AND SAFETY OF LATANOPROST VERSUS THE PILOCARPINE/TIMOLOL MALEATE FIXED COMBINATION IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION		1147.00	11106
	J.Ka&#322;u&#380;ny, Poland ; R.Sobecki, Poland ; K.Czechowicz-Janicka, Poland ; D.Kecik, Poland ; J.Stewart, USA ; W.Stewart, USA (*)			
0	INCREASE OF SERUM ALANINE / ASPARATE TRANSFERASE ASSOCIATED WITH PROSTAGLANDIN ANTI-GLAUCOMA DRUGS		1195.00	11177
	X.Wu, China ; L.Wu, China (*)			
0	OUR INITIAL EXPERIENCE OF SELECTIVE LASER TRABECULOPLASTY IN A CLINIC SETTING		1110.00	11088
	M.Ramchandani, UK (*) ; A.Gupta, UK ; A.Sampson, UK ; C.Davison, UK			
0	EPIGALLOCATECHIN GALLATE RELAXES THE BOVINE OPHTHALMIC ARTERY VIA A PHOSPHOINOSITIDE 3-KINASE-AKT-NITRIC OXIDE-CGMP SIGNALLING PATHWAY		1236.00	11197
	M.Lograno, Italy (*) ; M.Romano, Italy ; F.Nicoletti, Italy			
0	THE ENCYCLOPEDIA OF TOPICAL GLAUCOMA MEDICATION: EVIDENCE FROM RANDOMISED CONTROLLED TRIALS		1119.00	11091
	C.Lee, UK (*) ; F.Buckley, UK ; S.Costello, UK ; S.Kelly, UK			
0	SELECTIVE LASER TRABECULOPLASTY IN CORRECTION OF OPHTHALMOTONUS IN PSEUDOPHAKIC EYES IN PATIENTS WITH PREVIOUSLY OPERATED OPEN-ANGLE GLAUCOMA		1091.00	11079
	E.Tumanyan, Russia ; .Ivanova, Russia ; T.Lyubimova, Russia (*) ; E.Farazheva, Russia			

**Saturday 1 March**

1315 - 1400

Poster Area

**Poster Session II**

Chair

350/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference I
0	TREATMENT OF DIFFICULT-TO-TREAT GLAUCOMA AND OCULAR HYPERTENSION PATIENTS: A SURVEY OF GERMAN OPHTHALMOLOGISTS IN PRIVATE PRACTICE U.Thelen, Germany (*) ; C.Vorwerk, Germany ; P.Buchholz, Germany		1173.00	11134
0	LATANOPROST VERSUS USUAL CARE IN GLAUCOMA OR OCULAR HYPERTENSION: A RANDOMIZED, 36-MONTH, EFFICACY AND SAFETY STUDY IN SWEDEN AND FINLAND B.Fristrom, Sweden (*) ; H.Uusitalo, Finland ; S.Forsman, Sweden ; E.Berglund, Sweden		1140.00	11102
0	COMPARISON OF TWICE DAILY AND THREE TIMES DAILY DOSING OF DORZOLAMIDE IN OCULAR HYPERTENSIVE AND GLAUCOMA PATIENTS TREATED WITH LATANOPROST A.Lupinacci, USA (*) ; P.Netland, USA ; K.Fung, USA ; D.Evans, USA ; Y.Zhao, USA		1247.00	11286
0	EVALUATION OF FIX COOMBINATIONS OF PROSTAGLANDINS ANALOGUES J.Kelly Rigollet, Spain (*) ; J.Ondategui Garcia, Spain ; L.Lop Menal, Spain		1257.00	11211
0	PUPILLOGRAPHY IN THE SERVICE OF IDENTIFYING OPTIC NEUROPATHY AND NEURODEGENERATIVE DISEASES G.Kandel, USA (*) ; P.Trombley, USA		1251.00	11208
0	EFFECTIVENESS OF DORZOLAMIDE-TIMOLOL (COSOPT®) IN PATIENTS WHO WERE TREATMENT NAÏ VE FOR OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION A.Crichton, Canada ; P.Harasymowycz, Canada ; C.Hutnik, Canada ; B.Rama ; S.Boucher ; F.Ibrahim ; A.Rifkind ; L.Solomon, Canaad ; C.Liao, Canada ; T.Koulis, Canada ; J.Sampalis, Canada ; N.Bastien, Canada (*)		1087.00	11077
0	MONOTHERAPY BY DICLO-F DROPS IN POSTOPERATIVE TREATMENT OF PATIENTS AFTER ANTIGLAUCOMA OPERATION V.Egorov, Russia ; A.Postupaev, Russia ; A.Vasiliev, Russia ; A.Egorova, Russia (*)		1036.00	11030
0	COMBINED LASER INTERVENTIONS BY THE SELECTIVE LASER TRABECULOPLASTIC IN TREATMENT OF PATIENTS WITH NARROW-AND OPEN ANGLE GLAUCOMA. N.Ereskin, Russia (*) ; A.Zahidov		1155.00	9794
0	EVALUATE THE EFFECTS OF USING LOCAL STEROIDS ON OCCURANCE OF GLAUCOMA IN THE EYES B.Saberi, Iran (*)		1283.00	11217
0	PROTEOMIC EFFECTS FROM SERUM OF PATIENTS WITH GLAUCOMA ON RETINAL GANGLION CELLS AS NEW NEUROPROTECTIVE DRUG TARGETS K.Bell, Germany (*) ; G.Seigel, USA ; N.Pfeiffer, Germany ; F.Grus, Germany		1250.00	11207
0	THE COMEBACK OF ENDOSCOPIC CYCLOPHOTOCOAGULATION: A VALUABLE OPTION FOR GLAUCOMA PATIENTS O.Chan, China (*) ; N.Yuen, China		1047.00	11058
0	HYPOTENSIVE PREPARATION OF PATIENTS BEFORE ANTIGLAUCOMA OPERATION V.Egorov, Russia ; A.Postupaev, Russia ; A.Vasiliev, Russia ; A.Egorova, Russia (*)		1037.00	11030

**Saturday 1 March**

1315 - 1400

Poster Area

**Poster Session II**

Chair

350/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference I
0	ORAL CYTIDINE-5'-DIPHOSPHOCHOLINE (CITICOLINE) EFFECTS ON HAEMATOLOGICAL AND HAEMODYNAMIC PARAMETERS F.De Gregorio, Italy (*) ; G.Stecchi, Italy ; R.Bosia, Italy ; L.Colao, Italy		1063.00	11066
0	EVALUATION OF INTRAOCULAR PRESSURE IN 100 MYOPIC PATIENT IN MASHHAD M.shaygan, Iran (*) ; A.bloorian		1099.00	11084
0	IOP AND REFRACTIVE SURGERY C.Feinbaum, Germany (*)		1258.00	11212
0	BACTERIAL ENDOPHTHALMITIS TREATED WITH LINEZOLID S.Garcia-Delpech, Spain (*) ; D.Salom, Spain ; P.Udaondo, Spain ; M.Diaz-Llopis, Spain ; J.Romero, Spain		1267.00	11213
0	CLINICAL AND MICROBIAL EFFICACY OF BESIFLOXACIN COMPARED TO VEHICLE IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS E.Holland, USA ; M.Paterno, USA ; L.Brunner, USA ; T.Comstock, USA ; R.Siou-Mermet, France (*)		1052.00	8871
0	PHARMACOLOGICAL PROPHYLAXIS OF ENDOPHTHALMITIS IN CATARACT SURGERY A.Gierek-Lapinska, Poland ; E.Mrukwa-Kominek, Poland ; A.Pasternak, Poland (*) ; H.Wykrota, Poland ; K.Trzci&#261;kowski, Poland		1120.00	11092
0	THE PHARMACOLOGICAL EFFECT OF LEAF EXTRACTS OF PILIOSTIGMA THONNINGII (SCHUM) ON CHEMICALLY INDUCED/BACTERIALLY INFECTED/CORNEAL ULCERATION OF RABBIT EYES C.Asonye, Nigeria (*) ; E.Okenwa, Nigeria ; P.Alonge, Nigeria		1218.00	11186
0	TOPICAL GATIFLOXACIN 0.3% CAN PREVENT STAPHYLOCOCCUS AUREUS-INDUCED CLINICAL ENDOPHTHALMITIS IN A CLEAR CORNEA INCISION RABBIT MODEL R.Kowalski, USA (*) ; E.Romanowski, USA ; F.Mah, USA ; K.Yates, USA ; H.Weirback, USA ; L.Zhang, USA ; Y.Gordon, USA		1019.00	10250
0	INTRAVITREAL TOXICITY OF LINEZOLID IN A RABBIT MODEL P.Udaondo, Spain (*) ; S.Garcia-Delpech, Spain ; M.Garcia-Pous ; D.Salom, Spain ; B.Moratal, Spain ; M.Hernandez-Garfella, Spain ; M.Diaz-Llopis, Spain		1261.00	11213
0	BACTERIAL CONJUNCTIVITIS - CURCUMOMA - LONGA EYE DROPS ( CLINICAL STUDY) C.Srinivas, India (*)		1004.00	11021
0	EFFICACY AND SAFETY OF 0.18% SODIUM HYALURONATE (VISMEDÂ®) IN PATIENTS WITH BILATERAL MODERATE DRY EYE SYNDROME N.Ibnou-Zekri, Switzerland (*) ; V.Baeyens, Switzerland ; M.Zeher, Hungary ; A.Bereczki, Hungary ; Z.Sohajda, Hungary ; J.Marta, Hungary ; G.Deak, Hungary		1233.00	11168
0	ADALIMUMAB THERAPY FOR REFRACTORY UVEITIS: A PILOT STUDY M.Diaz-Llopis, Spain (*) ; S.Garcia-Delpech, Spain ; D.Salom, Spain ; P.Udaondo, Spain ; J.Romero, Spain ; F.Bosch, Spain		1263.00	11213
0	EVALUATION OF THE RELATIVE EFFICACY OF THE VARIOUS TREATMENT MODALITIES USED IN THE MANAGEMENT OF EALES' DISEASE A.Malik, UK (*) ; R.Zia, UK ; Z.Qazi, Pakistan		1011.00	11023

**Saturday 1 March**

1315 - 1400

Poster Area

**Poster Session II**

Chair

350/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference I
0	DR THEODOR AXENFELD AND HIS 'BACTERIOLOGY OF THE EYE' G.Balanikas, Greece (*) ; N.Ziakas, Greece ; D.Mikropoulos, Greece ; S.Kopsacheilis, Greece ; N.Georgiadis, Greece		1272.00	11192
0	COMPARATIVE CLINICAL STUDY OF PHLYCTENULAR CONJUNCTIVITIES WITH G GLABRA EYE DROPS C.Srinivas, India (*)		1002.00	3941
0	TREATMENT OF HERPETIC KERATOUVEITIS P.Schollmayer, Slovenia (*) ; A.Kraut, Slovenia		1269.00	10562
0	OFTALMOFERON IN ANTI - INFLAMMATORY AND SYMPTOMATIC THERAPY OF SECONDARY DRY EYE Y.Maychuk (*) ; D.Maychuk ; A.Chipanova ; E.Yany		1075.00	11073
0	SAFETY AND EFFICACY CLINIC TRIAL OF 0.03% MELOXICAM OPHTHALMIC SOLUTION VERSUS DICLOFENAC POSTSURGICAL OF LASIK REFRACTIVE SURGERY L.Baiza-Duran, Mexico (*) ; J.Quintana-Hau, Mexico ; R.Tornero-Montaño, Mexico ; L.Alanis-Villarreal, Mexico ; G.Avalos-Urzuza, Mexico ; J.Domene-Hinojosa, Mexico ; P.Gomez-Bastar, Mexico ; M.Ibañez-Hernandez, Mexico ; A.Mendez-Noble, Mexico ; G.Velasco-Gallegos, Mexico ; R.Velasco-Ramos, Mexico ; D.Viggiano-Austria, Mexico		1035.00	10949
0	EFFICACY AND SAFETY OF HYPOTONIC 0.18% SODIUM HYALURONATE SOLUTION IN MODERATE DRY EYE - STUDY OF THE OSMOLARITY OF TEAR FILM A.Rapisarda, Italy ; F.Battaglia, Italy ; L.Bossy, Switzerland (*)		1229.00	9731
0	CONFOCAL FLUORESCENCE MICROSCOPY ALLOWS 3D-RECONSTRUCTED CORNEAL EPITHELIUM (SKINETHICÂ®) MULTI-ANALYSES: APPLICATION TO THE TOXICOLOGICAL EVALUATION OF THE EYE-DROP PRESERVATIVE BENZALKONIUM CHLORIDE A.Pauly, France (*) ; C.Baudouin, France ; J.Warnet, France ; F.Brignole-Baudouin, France		1049.00	11059
0	THE ANTIOXIDANT AND ANTI-INFLAMMATORY AGENT N-ACETYL-L-CYSTEINE REDUCES DIABETIC DAMAGE IN INTACT BOVINE LENSES IN CULTURE E.Bormusov, Israel (*) ; Y.Dovrat, Israel ; A.Dovrat, Israel		1003.00	3327
0	PHARMACOLOGICAL TREATMENT OF CORNEOCONJUNCTIVAL INTRAEPITHELIAL NEOPLASIA J.Ibanez, Spain ; A.Mateo, Spain ; Z.Valyi, Spain (*) ; N.Lafuente, Spain ; J.Cristobal, Spain ; V.Huerta, Spain ; E.del Prado, Spain ; L.Lavilla, Spain		1259.00	11210
0	TRACHOMA - FROM THE DAWN OF HISTORY TO THE THRESHOLD OF 20TH CENTURY G.Balanikas, Greece (*) ; N.Ziakas, Greece ; S.Kopsacheilis, Greece ; D.Mikropoulos, Greece ; N.Georgiadis, Greece		1225.00	11192
0	NERVE GROW FACTOR: A THERAPEUTICAL APPROACH TO OCULAR SURFACE IN DOGS P.Dodi, Italy (*) ; C.Zanotti, Italy ; N.Costa, Italy ; L.Aloe, Italy		1072.00	11060
0	THE COST-EFFECTIVENESS OF SYSTANEÂ® IN THE MANAGEMENT OF OCULAR DRYNESS G.Berdeaux, France (*) ; J.Wlodarczyk, Australia ; C.Fairchild, USA		1150.00	3098

**Saturday 1 March**

1315 - 1400

Poster Area

**Poster Session II**

Chair

350/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference I
0	ACUTE BILATERAL KERATOCONJUNCTIVITIS AND MONOLATERAL ANTERIOR UVEITIS CAUSED BY CYTOSINE-ARABINOSIDE IN A DOG P.Dodi, Italy (*) ; E.Bianchi, Italy		1053.00	11060
0	THE PREVALENCE OF ASTIGMATISM IN PATIENTS WITH MYOPIA A.bolourian, Iran (*) ; M.shaygan		1100.00	11085
0	EVALUATION OF EFFECTIVENESS AND SAFETY OF FLIDOCAIN GEL AS AN ANESTHETIC AGANT IN PHACO CATARACTS SURGERY G.Aslanzadeh, Iran (*) ; D.Gharabaghi, Iran ; M.Parish, Iran ; R.Nouri Nia, Iran ; K.Sedaghat, Iran		1182.00	11151
0	OCULAR COMPLICATIONS OF AMIODARONE THERAPY I.Zolog, Romania (*) ; M.Munteanu, Romania ; E.Popovici, Romania		1039.00	11020
0	TOPICAL KINOSTATÂ® AMELIORATES SUGAR CATARACTS IN DOGS P.Kador, USA (*) ; M.Wyman, USA ; D.Betts, USA ; K.Blesing, USA ; J.Randazzo, USA ; H.Jin, USA		1043.00	11007
0	TOPOGRAPHY-GUIDED PRK COMBINED WITH COLLAGEN CROSS-LINKING TREATMENT OF REFRACTIVE ERRORS IN EYES WITH KERATOCONUS V.Kozobolis, Greece (*) ; H.Sideroudi, Greece ; M.Gkika, Greece ; A.Aristeidou, Greece		1242.00	11201
0	ART OF LASIK EYE SURGERY A.Gulani, USA (*)		1181.00	5662
0	CYCLOSPORIN ELUTING IMPLANT FOR PREVENTION AND TREATMENT OF CORNEAL GRAFT REJECTION J.Tauber, USA (*)		1085.00	9046
0	SECONDARY DRY EYE IN PATIENTS WITH SEASONAL ALLERGIC CONJUNCTIVITIS. THE USE OF ARTIFICIAL TEARS AND ANTI-INFLAMMATORY THERAPY D.Maychuk, Russia (*) ; L.Chilingarijan, Russia		1094.00	7725